DcR3在肝癌中的表达及对肝癌细胞生长调控、迁移的影响和在凋亡中作用的研究
|
摘要
目的
诱捕受体3(Decoy receptor 3,DcR3)是肿瘤坏死因子受体超家族的新成员之一,在多种恶性肿瘤中呈现过表达。本文通过研究原发性肝细胞癌(hepatocellular carcinoma,HCC)组织及肝癌细胞系中DcR3 mRNA和蛋白的表达情况及其与临床病理特征之间的关系,阐明DcR3在肝癌发生、发展及复发转移过程中的作用;同时探讨DcR3表达与肝癌细胞凋亡的关系;并且观察将DcR3中和性抗体加入表达该基因的肝癌细胞系后,肝癌细胞生长增殖、运动迁移、凋亡及对顺铂敏感性等各种细胞生物学特性的变化。
材料与方法
①应用半定量逆转录-聚合酶链反应RT-PCR方法,检测DcR3 mRNA在69例肝癌及癌旁组织中的表达和相对含量,分析DcR3 mRNA的相对含量与肝癌临床病理特征的关系。
②125例HCC、48例癌旁、64例肝硬化组织和25例正常肝组织构建肝癌组织微阵列。应用免疫组织化学方法(EnVision法)检测DcR3蛋白的表达水平,并分析其与HCC临床病理特征的关系。
③应用半定量RT-PCR,免疫组织化学,脱氧核糖核酸末端转移酶介导的缺口末端标记(TUNEL)及DNA电泳技术检测39例HCC及癌旁肝组织中DcR3mRNA及蛋白的表达和凋亡情况,并分析DcR3表达与细胞凋亡的关系。
④RT-PCR分析人肝癌细胞系HepG2,HepB3,SMMC-7721,bel-7402,bel-7405,癌旁肝细胞系QSG-7701及正常肝细胞系HL-7702 DcR3的mRNA水平;免疫细胞化学检测各个细胞系的DcR3蛋白表达水平;将DcR3中和性抗体加入肝癌细胞系中,通过MTT检测不同浓度DcR3中和性抗体作用于不同肝癌细胞存活率,挑选实验细胞株及DcR3中和性抗体最佳作用时间和作用浓度;免疫细胞化学检测DcR3中和性抗体加入后肝癌细胞DcR3蛋白表达差异;通过绘制细胞生长曲线以及集落形成实验来分析生长增殖特性;流式细胞仪(FCM)检测该抗体对细胞周期的影响;通过FCM,TUNEL染色,DNA ladder,电镜观察分析其对凋亡的影响;通过划痕实验分析DcR3对肝癌细胞迁移能力的影响;检测加入DcR3中和性抗体后hepG2对化疗药物顺铂敏感性的改变。
结果
①69例原发性肝细胞癌组织中,67例标本可扩增出426bp的条带,DcR3mRNA的阳性表达率为97.10%,明显高于癌旁组织DcR3 mRNA的阳性表达率76.81%(53/69,P＜0.01);癌组织中DcR3 mRNA相对含量明显高于癌旁组织(P＜0.01);序列分析发现其两例病例序列mRNA与源序列比较均有4个不同的碱基改变;DcR3 mRNA表达与转移复发和肿瘤大小有关,与年龄、性别、分化程度、临床分期、有无肝硬化、AFP、门脉癌栓、包膜浸润、肿瘤结节及HBsAg无明显相关。
②组织微阵列利用率为96.56%(253/262);HCC组织中的DcR3蛋白的阳性率73.33%(88/120)明显高于癌旁54.17%(26/48,P=0.017)、肝硬化组织37.10%(23/62,P=0.000)以及正常肝组织8.70%(2/23,P=0.000)。癌旁组织和肝硬化组织中的DcR3蛋白阳性率明显高于正常肝组织(P=0.000,P=0.005);HCC中临床TNM分期Ⅰ,Ⅱ期DcR3阳性率61.76%(42/68)明显低于Ⅲ,Ⅳ期88.46%(46/52,P=0.001);HCC中无转移组DcR3阳性率58.82%(20/34)明显低于转移组96.67%(29/30,P=0.000);DcR3表达率在AFP≥400μg/L组80.82%(59/73)、有门脉癌栓组91.30%(42/46)、包膜浸润组84.34%(70/83)和多个肿瘤结节组89.13%(41/46)分别明显高于AFP＜400μg/L组61.70%(29/47,P=0.021)、无门脉癌栓组62.16%(46/74,P=0.000)、无包膜浸润组48.65%(8/37,P=0.000)及单个肿瘤结节组63.51%(47/74,P=0.002)。DcR3表达与年龄、性别、分化程度、有无肝硬化及肿瘤直径无关。
③39例肝癌组织中,细胞凋亡指数(AI)及DNA ladder阳性率均明显低于癌旁组织(P=0.000);肝细胞凋亡与转移、临床分期和包膜浸润有关,与年龄、性别、分化程度、有无肝硬化、AFP、门脉癌栓、肿瘤大小、肿瘤结节及HBsAg无关。相关性分析显示AI与DcR3 mRNA及蛋白表达均呈负相关(r=-0.34,P=0.002;r=-0.679,P=0.000),与DNA ladder阳性率呈正相关(r=0.62,P=0.000)。DcR3 mRNA与蛋白表达呈正相关(1=0.419,P=0.000)。
④5种肝癌细胞系中均有DcR3mRNA和蛋白的表达,癌旁肝细胞系QSG-7701及正常肝细胞系HL-7702均无DcR3mRNA和蛋白的表达;选择HepG2为实验靶细胞,DcR3中和性抗体最佳实验浓度为0.8mg/L,作用时间48小时;加入DcR3中和性抗体后,HepG2肝癌细胞株DcR3蛋白表达明显减弱;加入DcR3抗体的细胞其生长增殖能力和集落形成能力均显著下降(P＜0.01);DcR3中和性抗体使细胞周期阻滞在G1/S期(P＜0.01)。同时凋亡明显增加(P＜0.01);细胞迁移能力也明显被抑制(P＜0.01);加入DcR3中和性抗体后顺铂作用下肝癌细胞细胞增殖存活率明显下降(P＜0.01)。
结论
①原发性肝细胞癌组织和肝癌细胞系中,DcR3 mRNA和蛋白均表达增高。DcR3 mRNA和蛋白的高表达在原发性肝细胞癌的发生、发展及转移复发过程中可能发挥重要的作用;
②原发性肝细胞癌DcR3 mRNA表达产物可能存在碱基改变;
③应用组织芯片大规模高效检测临床组织样本是可行的,具有快速、方便、经济、准确的特点;
④DcR3的高表达可抑制凋亡;
⑤DcR3中和性抗体能显著抑制肝癌细胞的生长和迁移并促进凋亡的发生并且能增加对顺铂的敏感性,提示该基因在肝癌的发生发展、凋亡及浸润转移中发挥重要作用,并有望在临床治疗中广泛应用。
Objective
Decoy receptor 3(DcR3),a newly identified member of the tumor necrosis factor receptor(TNFR)super-family,is over-expressed in many various kinds of malignant tumors.The objective of the research is to investigate the expression of DcR3 mRNA and protein in hepatocellular carcinoma(HCC)tissues and HCC cell lines and their correlations with clinicopathologic features,and to elucidate its role in tumorigenesis,development,recrudescence and metastasis, as well as to explore the relationship between the expression of DcR3 and the apoptosis in HCC.Then to observe the change of the biological characteristics(growth and proliferation,movement and transference,apoptosis,sensitivity to CDDP)in the hepatocellular carcinoma cell line with positive DcR3 expression adding the neutralization antibody DcR3.
Materials and Methods
①The expression of DcR3 mRNA was detected by semi-quantitive reverse transcription-polymerase chain reaction(RT-PCR)in 69 cases of HCC and the adjacent-tumor liver tissues.The relationship between the relative content of DcR3 mRNA and clinicopathological features of HCC was analyzed.
②The tissue microarrays comprised 125 cases of HCC tissues, 48 adjacent-tumor liver tissues,64 liver cirrhosis tissues and 25 normal liver tissues,Immunohistochemistry(EnVision method)was employed to detect the expression of DcR3 proteins.Statistic analysis was made to figure out the correlation between the expression and the clinicopathological features of HCC
③The mRNA and protein expression of DcR3 were detected in 39 cases of HCC and their para-tumor tissues by RT-PCR and immunohistochemistry,respectively.The apoptosis was evaluated by the method of terminal deoxynucleotidyl transferase mediated dUTP nick end labeling(TUNEL)and DNA agarose electrophoresis.Statistic analysis was made to figure out the correlation among the DcR3 expression,apoptosis and the clinicopathological features of HCC.
④Human hepatocellular carcinoma cell lines:HepG2,HepB3, SMMC-7721,bei-7402,bel-7405:liver cell line of para- tumor tissues QSG-7701 and normal liver cell line HL-7702 were harvested without any stimulation.The mRNA expression of DcR3 was detected by RT-PCR and the expression of DcR3 protein was detected by immunocytochemistry.The neutralization antibody DcR3 was added into different liver cancer cell lines and the cell livability rate was detected to decide the cell line for the following experiments and also to search the best working time and concentration of the neutralization antibody DcR3 by MTT assay.The difference of the DcR3 protein expression in hepatocellular carcinoma cell line was checked by immunocytochemistry after adding the neutralization antibody DcR3.The cellular proliferation was examined by cell growth curve and colony formation assay;The changes of cell cycle of cells were analyzed by flow cytometry(FCM);The apoptosis was explored by FCM, DNA ladder,TUNEL and electron microscope;The transferring ability was investigated by the wound healing test;And the sensitivity to Cisplatin(CDDP)of the hepatocellular carcinoma cell line was detected by MTT assay with neutralization antibody DcR3.
Results
①In 69 cases of HCC tissues,426 bp bands were detected in 67 cases,the positive rate of DcR3 mRNA expression was 97.10%,which is significantly higher than that in adjacent-tumor liver tissues 76.81%(53/69,P＜0.01).The relative content of DcR3 mRNA in HCC was significantly higher than that in the adjacent-tumor liver tissues (P＜0.01).Sequencing analysis showed 4 different point mutations in the DcR3 gene mRNA of HCC in two cases of positive amplification products.The expression was associated with metastasis and the tumor size but had no correlation with age,gender,differentiation grades,clinical stages,cirrhosis,AFP,portal vein tumor embolus,capsular infiltration,tumor nodes or HBsAg.
②There were 253 cases that could be used in the tissue microarrays(utilization rate was 96.56%,253/262);The positive rate of DcR3 in HCC tissues was 73.33%(88/120),significantly higher than that in the adjacent-tumor liver tissues 54.17%(26/48, P=0.017),cirrhosis tissues 37.10%(23/62,P=0.000)and the normal liver tissues 8.70%(2/23,P=0.000).The positive rate of DcR3 in adjacent-tumor tissues and cirrhosis tissues were both significantly higher than that in the normal liver group(P=0.000,P=0.005); The positive rate of DcR3 in HCC tissues in the clinical TNMstageⅠ,Ⅱwas 61.76%(42/68),obviously lower than that in the stageⅢ,Ⅳ88.46%(46/52,P=0.001);The positive rate of DcR3 in the cases without metastasis within 20 months was 58.82%(20/34), significantly lower than that in the group with metastasis 96.67% (29/30,P=0.000);The positive rates DcR3 in the groups of AFP≥400μg/L 80.82%(59/73),portal vein tumor embolus 91.30% (42/46),capsular infiltration 84.34%(70/83)and multiple tumor nodes 89.13%(41/46)were significantly higher than that in the groups of AFP＜400μg/L 61.70%(29/47,P=0.021),without tumor embolus 62.16% (46/74,P=0.000),with no capsular infiltration 48.65%(8/37, P=0.000)and single node 63.51%(47/74,P=0.002).It was not associated with patients' age,sex,histological classification, cirrhosis or tumor size.
③In 39 cases of HCC tissues,the apoptosis index(AI)and the positive rate of DNAladder in HCC were both significantly lower than that in the non-cancerous group(P=0.000).The AI was related to metastasis,clinical TNM stages and capsular infiltration but had no correlation with age,gender,histological differentiation grades,cirrhosis,plasma AFP levels,portal vein tumor embolus, tumor sizes,number of the tumor nodes or HBsAg.The relative analysis showed that there were negative correlations between AI and the expression of DcR3 mRNA and protein in HCC(r=-0.34,P=0.002; r=-0.679,P=0.000).There was positive correlation between the positive rate of DNA ladder and the expression of DcR3 mRNA and protein in HCC(r=0.62,P=0.000).The expression of DcR3 mRNA was positively related to the expression of protein(r=0.419,P=0.000).
④The all of 5 kinds of human hepatocellular carcinoma cell lines expressed DcR3 in mRNA and protein,while QSG-7701 and HL-7702 did not.HepG2 was chosen as the target cell lines for the experiments with the best concentration of neutralization antibody DcR3 0.8mg/L, best time 48h.The DcR3 protein expression became weakening in HepG2 after the DcR3 neutralization antibody DcR3;The cell viability, growing speed and colony formation ability were decreased obviously by adding DcR3-Ab(P＜0.01).The progression of the cell cycle was arrested in Gl/S-phase remarkably induced byDcR3-Ab(P＜0.01); The apoptosis was also significantly increased(P＜0.01);The transferring ability was significantly inhibited(P＜0.01)and the livability of the liver cells with CDDP was decreased by DcR3-Ab.
Conclusions
①DcR3 mRNA and protein are both over-expressed in HCC tissues and cell lines.The over-expression of DcR3 mRNA and protein may play an important role in the process of carcinogenesis,progression, recrudescence and metastasis in HCC;
②Point mutation of the DcR3 gene might exist in HCC;
③Tissue microarrays techniqueis a feasible,rapid,economic and accurate approach for screening clinical tissue specimens on a large scale;
④The over-expression of DcR3 might inhibit the apoptosis of HCC cells;
⑤DcR3 neutralization antibody can restrain the growth and movement,accelerate the apoptosis of the HCC cells,meanwhile increase the sensitivity to CDDP.The DcR3 gene plays an important role in origination,progression and metastasis of liver cancer and it is hopeful to be applied in the future clinical therapy to hepatocellular carcinoma.
诱捕受体3(Decoy receptor 3,DcR3)是肿瘤坏死因子受体超家族的新成员之一,在多种恶性肿瘤中呈现过表达。本文通过研究原发性肝细胞癌(hepatocellular carcinoma,HCC)组织及肝癌细胞系中DcR3 mRNA和蛋白的表达情况及其与临床病理特征之间的关系,阐明DcR3在肝癌发生、发展及复发转移过程中的作用;同时探讨DcR3表达与肝癌细胞凋亡的关系;并且观察将DcR3中和性抗体加入表达该基因的肝癌细胞系后,肝癌细胞生长增殖、运动迁移、凋亡及对顺铂敏感性等各种细胞生物学特性的变化。
材料与方法
①应用半定量逆转录-聚合酶链反应RT-PCR方法,检测DcR3 mRNA在69例肝癌及癌旁组织中的表达和相对含量,分析DcR3 mRNA的相对含量与肝癌临床病理特征的关系。
②125例HCC、48例癌旁、64例肝硬化组织和25例正常肝组织构建肝癌组织微阵列。应用免疫组织化学方法(EnVision法)检测DcR3蛋白的表达水平,并分析其与HCC临床病理特征的关系。
③应用半定量RT-PCR,免疫组织化学,脱氧核糖核酸末端转移酶介导的缺口末端标记(TUNEL)及DNA电泳技术检测39例HCC及癌旁肝组织中DcR3mRNA及蛋白的表达和凋亡情况,并分析DcR3表达与细胞凋亡的关系。
④RT-PCR分析人肝癌细胞系HepG2,HepB3,SMMC-7721,bel-7402,bel-7405,癌旁肝细胞系QSG-7701及正常肝细胞系HL-7702 DcR3的mRNA水平;免疫细胞化学检测各个细胞系的DcR3蛋白表达水平;将DcR3中和性抗体加入肝癌细胞系中,通过MTT检测不同浓度DcR3中和性抗体作用于不同肝癌细胞存活率,挑选实验细胞株及DcR3中和性抗体最佳作用时间和作用浓度;免疫细胞化学检测DcR3中和性抗体加入后肝癌细胞DcR3蛋白表达差异;通过绘制细胞生长曲线以及集落形成实验来分析生长增殖特性;流式细胞仪(FCM)检测该抗体对细胞周期的影响;通过FCM,TUNEL染色,DNA ladder,电镜观察分析其对凋亡的影响;通过划痕实验分析DcR3对肝癌细胞迁移能力的影响;检测加入DcR3中和性抗体后hepG2对化疗药物顺铂敏感性的改变。
结果
①69例原发性肝细胞癌组织中,67例标本可扩增出426bp的条带,DcR3mRNA的阳性表达率为97.10%,明显高于癌旁组织DcR3 mRNA的阳性表达率76.81%(53/69,P＜0.01);癌组织中DcR3 mRNA相对含量明显高于癌旁组织(P＜0.01);序列分析发现其两例病例序列mRNA与源序列比较均有4个不同的碱基改变;DcR3 mRNA表达与转移复发和肿瘤大小有关,与年龄、性别、分化程度、临床分期、有无肝硬化、AFP、门脉癌栓、包膜浸润、肿瘤结节及HBsAg无明显相关。
②组织微阵列利用率为96.56%(253/262);HCC组织中的DcR3蛋白的阳性率73.33%(88/120)明显高于癌旁54.17%(26/48,P=0.017)、肝硬化组织37.10%(23/62,P=0.000)以及正常肝组织8.70%(2/23,P=0.000)。癌旁组织和肝硬化组织中的DcR3蛋白阳性率明显高于正常肝组织(P=0.000,P=0.005);HCC中临床TNM分期Ⅰ,Ⅱ期DcR3阳性率61.76%(42/68)明显低于Ⅲ,Ⅳ期88.46%(46/52,P=0.001);HCC中无转移组DcR3阳性率58.82%(20/34)明显低于转移组96.67%(29/30,P=0.000);DcR3表达率在AFP≥400μg/L组80.82%(59/73)、有门脉癌栓组91.30%(42/46)、包膜浸润组84.34%(70/83)和多个肿瘤结节组89.13%(41/46)分别明显高于AFP＜400μg/L组61.70%(29/47,P=0.021)、无门脉癌栓组62.16%(46/74,P=0.000)、无包膜浸润组48.65%(8/37,P=0.000)及单个肿瘤结节组63.51%(47/74,P=0.002)。DcR3表达与年龄、性别、分化程度、有无肝硬化及肿瘤直径无关。
③39例肝癌组织中,细胞凋亡指数(AI)及DNA ladder阳性率均明显低于癌旁组织(P=0.000);肝细胞凋亡与转移、临床分期和包膜浸润有关,与年龄、性别、分化程度、有无肝硬化、AFP、门脉癌栓、肿瘤大小、肿瘤结节及HBsAg无关。相关性分析显示AI与DcR3 mRNA及蛋白表达均呈负相关(r=-0.34,P=0.002;r=-0.679,P=0.000),与DNA ladder阳性率呈正相关(r=0.62,P=0.000)。DcR3 mRNA与蛋白表达呈正相关(1=0.419,P=0.000)。
④5种肝癌细胞系中均有DcR3mRNA和蛋白的表达,癌旁肝细胞系QSG-7701及正常肝细胞系HL-7702均无DcR3mRNA和蛋白的表达;选择HepG2为实验靶细胞,DcR3中和性抗体最佳实验浓度为0.8mg/L,作用时间48小时;加入DcR3中和性抗体后,HepG2肝癌细胞株DcR3蛋白表达明显减弱;加入DcR3抗体的细胞其生长增殖能力和集落形成能力均显著下降(P＜0.01);DcR3中和性抗体使细胞周期阻滞在G1/S期(P＜0.01)。同时凋亡明显增加(P＜0.01);细胞迁移能力也明显被抑制(P＜0.01);加入DcR3中和性抗体后顺铂作用下肝癌细胞细胞增殖存活率明显下降(P＜0.01)。
结论
①原发性肝细胞癌组织和肝癌细胞系中,DcR3 mRNA和蛋白均表达增高。DcR3 mRNA和蛋白的高表达在原发性肝细胞癌的发生、发展及转移复发过程中可能发挥重要的作用;
②原发性肝细胞癌DcR3 mRNA表达产物可能存在碱基改变;
③应用组织芯片大规模高效检测临床组织样本是可行的,具有快速、方便、经济、准确的特点;
④DcR3的高表达可抑制凋亡;
⑤DcR3中和性抗体能显著抑制肝癌细胞的生长和迁移并促进凋亡的发生并且能增加对顺铂的敏感性,提示该基因在肝癌的发生发展、凋亡及浸润转移中发挥重要作用,并有望在临床治疗中广泛应用。
Objective
Decoy receptor 3(DcR3),a newly identified member of the tumor necrosis factor receptor(TNFR)super-family,is over-expressed in many various kinds of malignant tumors.The objective of the research is to investigate the expression of DcR3 mRNA and protein in hepatocellular carcinoma(HCC)tissues and HCC cell lines and their correlations with clinicopathologic features,and to elucidate its role in tumorigenesis,development,recrudescence and metastasis, as well as to explore the relationship between the expression of DcR3 and the apoptosis in HCC.Then to observe the change of the biological characteristics(growth and proliferation,movement and transference,apoptosis,sensitivity to CDDP)in the hepatocellular carcinoma cell line with positive DcR3 expression adding the neutralization antibody DcR3.
Materials and Methods
①The expression of DcR3 mRNA was detected by semi-quantitive reverse transcription-polymerase chain reaction(RT-PCR)in 69 cases of HCC and the adjacent-tumor liver tissues.The relationship between the relative content of DcR3 mRNA and clinicopathological features of HCC was analyzed.
②The tissue microarrays comprised 125 cases of HCC tissues, 48 adjacent-tumor liver tissues,64 liver cirrhosis tissues and 25 normal liver tissues,Immunohistochemistry(EnVision method)was employed to detect the expression of DcR3 proteins.Statistic analysis was made to figure out the correlation between the expression and the clinicopathological features of HCC
③The mRNA and protein expression of DcR3 were detected in 39 cases of HCC and their para-tumor tissues by RT-PCR and immunohistochemistry,respectively.The apoptosis was evaluated by the method of terminal deoxynucleotidyl transferase mediated dUTP nick end labeling(TUNEL)and DNA agarose electrophoresis.Statistic analysis was made to figure out the correlation among the DcR3 expression,apoptosis and the clinicopathological features of HCC.
④Human hepatocellular carcinoma cell lines:HepG2,HepB3, SMMC-7721,bei-7402,bel-7405:liver cell line of para- tumor tissues QSG-7701 and normal liver cell line HL-7702 were harvested without any stimulation.The mRNA expression of DcR3 was detected by RT-PCR and the expression of DcR3 protein was detected by immunocytochemistry.The neutralization antibody DcR3 was added into different liver cancer cell lines and the cell livability rate was detected to decide the cell line for the following experiments and also to search the best working time and concentration of the neutralization antibody DcR3 by MTT assay.The difference of the DcR3 protein expression in hepatocellular carcinoma cell line was checked by immunocytochemistry after adding the neutralization antibody DcR3.The cellular proliferation was examined by cell growth curve and colony formation assay;The changes of cell cycle of cells were analyzed by flow cytometry(FCM);The apoptosis was explored by FCM, DNA ladder,TUNEL and electron microscope;The transferring ability was investigated by the wound healing test;And the sensitivity to Cisplatin(CDDP)of the hepatocellular carcinoma cell line was detected by MTT assay with neutralization antibody DcR3.
Results
①In 69 cases of HCC tissues,426 bp bands were detected in 67 cases,the positive rate of DcR3 mRNA expression was 97.10%,which is significantly higher than that in adjacent-tumor liver tissues 76.81%(53/69,P＜0.01).The relative content of DcR3 mRNA in HCC was significantly higher than that in the adjacent-tumor liver tissues (P＜0.01).Sequencing analysis showed 4 different point mutations in the DcR3 gene mRNA of HCC in two cases of positive amplification products.The expression was associated with metastasis and the tumor size but had no correlation with age,gender,differentiation grades,clinical stages,cirrhosis,AFP,portal vein tumor embolus,capsular infiltration,tumor nodes or HBsAg.
②There were 253 cases that could be used in the tissue microarrays(utilization rate was 96.56%,253/262);The positive rate of DcR3 in HCC tissues was 73.33%(88/120),significantly higher than that in the adjacent-tumor liver tissues 54.17%(26/48, P=0.017),cirrhosis tissues 37.10%(23/62,P=0.000)and the normal liver tissues 8.70%(2/23,P=0.000).The positive rate of DcR3 in adjacent-tumor tissues and cirrhosis tissues were both significantly higher than that in the normal liver group(P=0.000,P=0.005); The positive rate of DcR3 in HCC tissues in the clinical TNMstageⅠ,Ⅱwas 61.76%(42/68),obviously lower than that in the stageⅢ,Ⅳ88.46%(46/52,P=0.001);The positive rate of DcR3 in the cases without metastasis within 20 months was 58.82%(20/34), significantly lower than that in the group with metastasis 96.67% (29/30,P=0.000);The positive rates DcR3 in the groups of AFP≥400μg/L 80.82%(59/73),portal vein tumor embolus 91.30% (42/46),capsular infiltration 84.34%(70/83)and multiple tumor nodes 89.13%(41/46)were significantly higher than that in the groups of AFP＜400μg/L 61.70%(29/47,P=0.021),without tumor embolus 62.16% (46/74,P=0.000),with no capsular infiltration 48.65%(8/37, P=0.000)and single node 63.51%(47/74,P=0.002).It was not associated with patients' age,sex,histological classification, cirrhosis or tumor size.
③In 39 cases of HCC tissues,the apoptosis index(AI)and the positive rate of DNAladder in HCC were both significantly lower than that in the non-cancerous group(P=0.000).The AI was related to metastasis,clinical TNM stages and capsular infiltration but had no correlation with age,gender,histological differentiation grades,cirrhosis,plasma AFP levels,portal vein tumor embolus, tumor sizes,number of the tumor nodes or HBsAg.The relative analysis showed that there were negative correlations between AI and the expression of DcR3 mRNA and protein in HCC(r=-0.34,P=0.002; r=-0.679,P=0.000).There was positive correlation between the positive rate of DNA ladder and the expression of DcR3 mRNA and protein in HCC(r=0.62,P=0.000).The expression of DcR3 mRNA was positively related to the expression of protein(r=0.419,P=0.000).
④The all of 5 kinds of human hepatocellular carcinoma cell lines expressed DcR3 in mRNA and protein,while QSG-7701 and HL-7702 did not.HepG2 was chosen as the target cell lines for the experiments with the best concentration of neutralization antibody DcR3 0.8mg/L, best time 48h.The DcR3 protein expression became weakening in HepG2 after the DcR3 neutralization antibody DcR3;The cell viability, growing speed and colony formation ability were decreased obviously by adding DcR3-Ab(P＜0.01).The progression of the cell cycle was arrested in Gl/S-phase remarkably induced byDcR3-Ab(P＜0.01); The apoptosis was also significantly increased(P＜0.01);The transferring ability was significantly inhibited(P＜0.01)and the livability of the liver cells with CDDP was decreased by DcR3-Ab.
Conclusions
①DcR3 mRNA and protein are both over-expressed in HCC tissues and cell lines.The over-expression of DcR3 mRNA and protein may play an important role in the process of carcinogenesis,progression, recrudescence and metastasis in HCC;
②Point mutation of the DcR3 gene might exist in HCC;
③Tissue microarrays techniqueis a feasible,rapid,economic and accurate approach for screening clinical tissue specimens on a large scale;
④The over-expression of DcR3 might inhibit the apoptosis of HCC cells;
⑤DcR3 neutralization antibody can restrain the growth and movement,accelerate the apoptosis of the HCC cells,meanwhile increase the sensitivity to CDDP.The DcR3 gene plays an important role in origination,progression and metastasis of liver cancer and it is hopeful to be applied in the future clinical therapy to hepatocellular carcinoma.
引文
1 Pitti RM,Marsters SA,Lawrence DA,RoyM,Kischkel FC,Dowd P,Huang A,Donahue CJ,Sherwood SW,Baldwin DT,Godowski PJ,Wood WI,Gurney AL,Hillan KJ,Cohen RL,Goddard AD,Botstein D,Ashkenazi A.Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.Nature,1998,396(6712):699-703.
2 Bai C,ConnollyB,MetzkerML,Hilliard CA,Liu X,Sandig V,Soderman A,Galloway SM,Liu Q,Austin CP,Caskey CT.Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.Proc Natl Acad Sci U S A,2000,97(3):1230-1235.
3 Schwendel A,Richard F,Langreck H,Kaufmann O,Lage H,Winzer KJ,Petersen I,Dietel M.Chromosome alterations in breast carcinomas:frequent involvement of DNA losses including chromosomes 4q and 21q.Br J Cancer,1998,78(6):806-811.
4 Sakakura C,Mori T,Sakabe T,Ariyama Y,Shinomiya T,Date K,HagiwaraA,Yamaguchi T,Takahashi T,Nakamura Y,Abe T,Inazawa J.Gains,losses,and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization.Genes Chromosomes Cancer,1999,24(4):299-305.
5 Muleris M,AlmeidaA,Gerbault-Seureau M,Malfoy B,Dutrillaux B.Identification of amplified DNA sequences in breast cancer and their organization within homogeneously staining regions.Genes Chromosomes Cancer,1995,14(3):155-163.
6 Altura RA,Maris JM,Li H,Boyett JM,Brodeur GM,Look AT.Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization.Genes Chromosomes Cancer,1997,19(3):176-184.
7 ShinomiyaT, Mori T, AriyamaY, Sakabe T, FukudaY, Murakami Y, Nakamura Y, Inazawa J. Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer, 1999, 24(4):337-344.
8 Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y. The prognostic significance of Overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer, 2002, 5 (2): 61-68.
9 Jinguo Chen, Lurong Zhang, Sunghee Kim. Quantification and detection of DcR3, a decoy receptor in TNFR family. Journal of Immunological Methods, 285 (2004): 63-70.
10 Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.Int J Cancer, 2003, 105(5):724-732.
11 Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, Rochlitz C. DcR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. International Journal of Cancer, 2002, 102(3): 254-257.
12 Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res, 2001, 61 (6): 2759-2765.
13 Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y. Frequent gene amplification and Overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol (Berl), 2005 , 109 (3) :294-298.
14 Ohshima K,Haraoka S,Sugihara M,Suzumiya J,Kawasaki C,Kanda M,Kikuchi M.Amplification and expression of a decoy receptor for fas ligand(DcR3)in virus(EBV or HTLV-Ⅰ)associated lymphomas.Cancer Lett,2000,160(1):89-97.
15 Elnemr A,OhtaT,Yachie A,KayaharaM,KitagawaH,Fujimura T,Ninomiya I,Fushida S,Nishimura GI,Shimizu K,Miwa K.Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway.Int J Oncol,2001,18(2):311-316.
16 IbrahimSM,Ringel J,Schmidt C,Ringel B,MullerP,Koczan D,Thiesen HJ,Lohr M.Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.Pancreas,2001,23(1):72-79.
17 Tsuji S,Hosotani R,Yonehara S,Masui T,Tulachan SS,Nakajima S,Kobayashi H,Koizumi M,Toyoda E,Ito D,Kami K,Mori T,Fujimoto K,Doi R,Imamura M.Endogenous decoy receptor 3blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma,lnt J Cancer,2003,106(1):17-25.
18 Li H,Zhang L,Lou H,Ding I,Kim S,Wang L,Huang J,Di Sant'Agnese PA,Lei JY.Over-expression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.Am J Clin Pathol,2005,124(2):282-287.
19 Shen HW,Gao SL,Wu YL,Peng SY.Over-expression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.World J Gastroenterol,2005,11(38):5926-5930.
20 Yu KY,Kwon B,Ni J,Zhai Y,Ebner R,Kwon BS.A newly identified member of tumor necrosis factor receptor superfamily(TR6) suppresses LIGHT-mediated apoptosis.J Biol Chem,1999,274(20):13733-13736.
21 Maeda T,Hao C,Tron VA.Ultraviolet light(UV)regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes.J Cutan Med Surg,2001,5(4):294-298.
22 Edmondson HA,Steiner PE.Primary carcinoma of the liver:a study of 100 cases among 48,900 necropsies.Cancer,1954,7(3):462-503.
23 Tanaka S,Noguchi N,Ochiai T,Kudo A,Nakamura N,Ito K,Kawamura T,Teramoto K,Arii S.Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria:rationale for partial hepatectomy as first strategy.J Am Coll Surg,2007,204(1):1-6.
24 Tanaka H,Kubo S,TsukamotoT,ShutoT,Takemura S,Yamamoto T,Okuda T,Kanazawa A,Hirohashi K.Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria.Transplant Proc,2005,37(2):1254-1256.
25王毅军,杜智,吴尘轩,袁强,舒桂明,张淑萍.切缘冷冻对原发性肝癌切除术后局部复发的预防作用.中华普通外科杂志,2006,21(6):438-440.
26 Tang SH,Yang DH,Huang W,Zhou M,Zhou HK,Lu XH,Ye G.Differential promoter usage for insulin-like growth factor-Ⅱ gene in Chinese hepatocellular carcinoma with hepatitis B virus infection.Cancer Detect Prey,2006,30(2):192-203.
27白伟良,任重,潘子民,高红.KAI1基因在喉鳞癌中的表达及其临床意义.中华肿瘤杂志,2005,27(5):289-291.
28孙现军,左文述,马恒,侯文红,蔡淑萍,姜希宏.骨桥蛋白mRNA在胃癌中的表达及其临床意义.中华肿瘤杂志,2005,27(5):292-295.
29 Saiki RK,Scharf S,Faloona F,Mullis KB,Horn GT,Erlich HA,Arnheim N.Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.Science,1985,230(4732):1350-1354.
30吴育连,于俊秀,沈宏伟,韩冰,高顺良.血清TR6升高与胃癌淋巴转移分期的关系.中华外科杂志,2003,41(12):928-931.
31 Hwang SL,LinCL,Cheng CY,Lin FA,Lieu AS,Howng SL,Lee KS.Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery.Kaohsiung J Med Sci,2004,20(3):124-127.
32 Shi G,Mao J,Yu G,Zhang J,Wu J.Tumor vaccine based on cell surface expression of DcR3/TR6.Journal of Immunology,2005,174(8):4727-4735.
33 Wu YY,Chang YC,Hsu TL,Hsieh SL,Lai MZ.Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.The Journal of Biological Chemistry,2004,279(42):44211-44218.
34段伟宏,苏忠学,吴泰璜.DcR3反义RNA与顺铂对肝癌细胞凋亡影响的比较.中国现代普通外科进展,2005,8(2):90-92.
35 Ashkenazi A.Targeting death and decoy receptors of the tumour-necrosis factor superfamily.Nat Rev Cancer,2002,2(6):420-430.
36 Chang YC,Chan gu,Jackson DG,Hsieh SL.The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion.J Immunol,2006,176(1):173-180.
37 Yachnis AT,Trojanowski JQ.Studies of childhood brain tumors using immunohistochemistry and microwave technology:methodological considerations.J Neurosci Methods,1994,55(2):191-200.
38 Almqvist PM,Mah R,Lendahl U,Jacobsson B,Hendson G.Immunohistochemical detection of nestin in pediatric brain tumors.J Histochem Cytochem,2002,50(2):147-158.
39陈罡,罗殿中,李萍,王华.改进免疫组织化学SP法的探讨.广西医科大学学报,2005,22(1):138-139.
40 Watanabe A,Cornelison R,Hostetter G.Tissue microarrays:applications in genomic research.Expert Rev Mol Diagn,2005,5(2):171-181.
41 Rimm DL,Camp RL,Charette LA,Costa J,Olsen DA,Reiss M.Tissue microarray:a new technology for amplification of tissue resources.Cancer J,2001,7(1):24-31.
42 Donati V,Faviana P,Dell'omodarme M,Prati MC,Camacci T,De IesoK,Giannini R,Lucchi M,Mussi A,Pingitore R,Basolo F,Fontanini G.Applications of tissue microarray technology in immunohistochemistry:a study on c-kit expression in small cell lung cancer.Hum Pathol,2004,35(11):1347-1352.
43 Kononen J,Bubendorf L,Kallioniemi A,Barlund M,Schraml P,Leighton S,Torhorst J,Mihatsch MJ,Sauter G,Kallioniemi OP.Tissue microarray for high-throughput molecular profiling of tumor specimens.Nat Med,1998,4(7):844-847.
44李锦军,葛超,万大方,顾健人.高通量肿瘤组织-细胞系芯片技术平台的建立及应用.中华病理学杂志,2002,31(5):461-463.
45陈莉,李德春,朱远源.NET-1蛋白表达与肝癌临床病理因素相关性探讨,中华病理学杂志,2005,34(9):596-597.
46 Horvath L,Henshall S.The application of tissue microarrays to cancer research.Pathology,2001,33(2):125-129.
47 Shergill IS,Shergill NK,Arya M,Patel HR.Tissue microarrays:a current medical research tool.Curr Med Res Opin,2004,20(5):707-712.
48 Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.Breast Cancer Res Treat,2004,85(1):13-22.
49 Hoos A,Nissan A,Stojadinovic A,Shia J,Hedvat CV,Leung DH,Paty PB,Klimstra D,Cordon-Cardo C,Wong WD.Tissue microarray molecular profiling of early,node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res, 2002, 8(12): 3841-3849.
50 Mucci NR, Akdas G, ManelyS, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol, 2000, 31 (4): 406-414.
51 MochH, KononenT, Kallioniemi OP, Sauter G. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol, 2001, 8(1): 14-20.
52 West RB, van de Rijn M. The role of microarray technologies in the study of soft tissue tumours. Histopathology , 2006, 48(1) :22-31.
53 Hewitt SM. The application of tissue microarrays in the validation of microarray results. Methods Enzymol. 2006; 410(1):400—415.
54 Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol, 2002, 30(12): 1365-1372.
55 Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol, 2005, 115(3): 286-294.
56 Fevery J. Non-surgical treatment of hepatocellular carcinoma (HCC).Acta Gastroenterol Belg, 2000 , 63(2) :233-235.
57 Sturm JW, Keese M. Multimodal treatment of hepatocellular carcinoma (HCC). Onkologie, 2004, 27(3):294-303.
58 Shi G, LuoH, Wan X, Salcedo TW, Zhang J, Wu J. Mouse T cells receive costimulatory signals from LIGHT , a TNF family member. Blood, 2002, 100(9):3279-3286.
59 Wroblewski VJ, WitcherDR, Becker GW, Davis KA, DouS, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIOHr.Biochem Pharmacol,2003,65(4):657-667.
60 Ideker T,Thorsson V,Ranish SA,Christmas R,Buhler J,Eng JK,Bumgarner R,Goodlett DR,Aebersold R,Hood L.Integrated genomic and proteomic analyses of a systematically perturbed metabolic network.Science,2001,292(5518):929-934.
61 Kerr JF,Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics.Br J Cancer,1972,26(4):239-257.
62 Soria Gonzalez JE,Orea Solano M.Apoptosis.Rev Alerg Mex,2002,49(4):121-128.
63 Thompsin CB.Apoptosis in pathogenesis and treatment of disease.Science,1995,267(5302):1456-1462.
64郑建勇,李开宗,王为忠.肝癌组织中p27基因的表达及其与细胞凋亡的关系.世界华人消化杂志,2002,10(2):883-886.
65 Takahashi T,Tanaka M,Inazawa J,Abe T,Suda T,Nagata S.Human Fas ligand:gene structure,chromosomal location and species specificity.Int Immunol,1994,6(10):1567-1574.
66 Ju ST,Panka DJ,Cui H,Ettinger R,el-Khatib M,Sherr DH,Stanger BZ,Marshak-Rothstein A.Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.Nature,1995,373(6513):444-448.
67 Gajate C,Fonteriz RI,Cabaner C,Alvarez-Noves G,Alvarez-Rodriguez Y,Modolell M,Mollinedo F.Intracellular triggering of Fas,independently of FasL,as a new mechanism of antitumor ether lipid-induced apoptosis,lnt J Cancer,2000,85(5):674-682.
68 Gajate C,Del Canto-Janez E,Acuna AU,Amat-Guerri F,Geijo E,Santos-Beneit AM,Veldman RJ,Mollinedo F.Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.J Exp Med,2004,200(3):353-365.
69 Gajate C,Mollinedo F.The antitumor ether lipid ET-18-OCH(3)induces apoptosis through translocation and capping of Fas/CD95into membrane rafts in human leukemic cells.Blood,2001,98(13):3860-3863.
70 Kusakabe K,Otsuki Y,Kiso Y.Involvement of the fas ligand and fas system in apoptosis induction of mouse uterine natural killer cells.J Reprod Dev,2005,51(3):333-340.
71 Smyth MJ,Cretney E,Kelly JM,Westwood JA,Street SE,Yagita H,Takeda K,van Dommelen SL,Uegli-Esposti MA,Hayakawa Y.Activation of NK cell cytotoxicity.Mol Immunol,2005,42(4):501-510.
72 Pinkoski MJ,Brunner T,Green DR,Lin T.Fas and Fas ligand in gut and liver.Am J Physiol Gastrointest Liver Physiol,2000,278(3):354-366.
73 Suda T,Okazaki T,Naito Y,Yokota T,Arai N,Ozaki S,Nakao K,Nagata S.Expression of the Fas ligand in cells of T cell lineage.J Immunol,1995,154(8):3806-3813.
74 Siegel RM,Chan FK,Chun HJ,Lenardo MJ.The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.Nat Immunol,2000,1(6):469-474.
75 Zaks TZ,Chappell DB,Rosenberg SA,Restifo NP.Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor:selective rescue by caspase inhibition.J Immunol,1999,162(6):3273-3279.
76 Karas M,Zaks TZ,Yakar S,Dudley ME,LeRoith D.TCR stimulation protects CD8+T cells from CD95 mediated apoptosis.Hum Immunol,2001,62(1):32-38.
77 Wahlsten JL,Gitchell HL,Chan CC,Wiggert B,Caspi RR.Fas and Fas ligand expressed on cells of the immune system,not on the target tissue,control induction of experimental autoimmune uveitis.J Immunol,2000,165(10):5480-5486.
78 Beyaert R,Van Loo G,Heyninck K,Vandenabeele P.Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas.Int Rev Cytol,2002,214(1):225-272.
79 Sheikh MS,Fornace AJ Jr.Death and decoy receptors and p53-mediated apoptosis.Leukemia,2000,14(8):1509-1513.
80 Zhang J,Salcedo TW,Wan X,Ullrich S,Hu B,Gregorio T,Feng P,Qi S,Chen H,Cho YH,Li Y,Moore PA,Wu J.Modulation of T-cell responses to alloantigens by TR6/DcR3.J Clin Invest,2001,107(11):1459-1468.
81 Hayashi S,Miura Y,Nishiyama T,Mitani M,Tateishi K,Sakai Y,Hashiramoto A,Kurosaka M,Shiozawa S,Doita M.Decoy receptor 3expressed in rheumatoid synovial fibroblasts protects the cells against fas-induced apoptosis.Arthritis Rheum,2007,56(4):1067-1075.
82 Connolly K,Cho YH,Duan R,Fikes J,Gregorio T,LaFleur DW,Okoye Z,Salcedo TW,Santiago G,Ullrich S,Wei P,Windle K,Wong E,Yao XT,Zhang YQ,Zheng G,Moore PA.In vivo inhibition of Fas ligand-mediated killing by TR6,a Fas ligand decoy receptor.J Pharmacol Exp Ther,2001,298(1):25-33.
83 Wortinger MA,Foley JW,Larocque P,Witcher DR,Lahn M,Jakubowski JA,Glasebrook A,Song HY.Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3analogue,Immunology,2003,110(2):225-233.
84 Mauri DN,Ebner R,Montgomery RI,Kochel KD,Cheung TC,Yu GL,Ruben S,Murphy M,Eisenberg RJ,Cohen GH,Spear PG,Ware CF.LIGHT,a new member of the TNF superfamily,and lymphotoxin alpha are ligands for herpesvirus entry mediator.Immunity,1998, 8(1):21-30.
85 Gill RM,Ni J,Hunt JS.Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.Am J Pathol,2002,161(6):2011-2017.
86 Gill RM,Hunt JS.Soluble receptor(DcR3)and cellular inhibitor of apoptosis-2(cIAP-2)protect human cytotrophoblast cells against LIGHT-mediated apoptosis.Am J Pathol,2004,165(1):309-317.
87 Wan X,Zhang J,Luo H,Shi G,Kapnik E,Kim S,Kanakaraj P,Wu J.A TNF family member LIGHT transduces costimulatory signals into human T cells.J Immunol,2002,169(12):6813-6821.
88 Ware CF.Network communications:lymphotoxins,LIGHT,and TNF.Annu Rev Immunol.2005,23:787-819.
89 Morel Y,Truneh A,Costello RT,Olive D.LIGHT,a new TNF superfamily member,is essential for memory T helper cell-mediated activation of dendritic cells.Eur J Immunol,2003,33(11):3213-3219.
90 Yang D,Zhai Y,Zhang M.LIGHT,a new member of the TNF superfamily.J Biol Regul Homeost Agents,2OO2,16(3):2O6-210.
91 Chang YH,Hsieh SL,Chao Y,Chou YC,Lin WW.Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.J Biomed Sci,2005,12(2):363-375.
92 Chen MC,Hwang MJ,Chou YC,Chen WH,Cheng G,Nakano H,Luh TY,Mai SC,Hsieh SL.The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death.J Biol Chem,2003,278(18):16073-16081.
93 Scheu S,Alferink J,Potzel T,Barchet W,Kalinke U,Pfeffer K.Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis.J Exp Med,2002,195(12):1613-1624.
94 Migone TS,Zhang J,Luo X,Zhuang L,Chen C,Hu B,Hong JS,Perry JW,Chen SF,Zhou JX,Cho YH,Ullrich S,Kanakaraj P,Carrell J,Boyd E,Olsen HS,Hu G,Pukac L,Liu D,Ni J,Kim S,Gentz R,Feng P,Moore PA,Ruben SM,Wei P.TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.Immunity,2002,16(3):479-492.
95 Bamias G,Martin C 3rd,Marini M,Hoang S,Mishina M,Ross WG,Sachedina Mf,Friel CM,Mize J,Bickston SJ,Pizarro TT,Wei P,Cominelli F.Expression,localization,and functional activity of TL1A,a novel Th1-polarizing cytokine in inflammatory bowel disease.J Immunol,2003,171(9):4868-4874.
96 Wen L,Zhuang L,Luo X,Wei P.TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1cells.J Biol Chem,2003,278(40):39251-39258.
97 Green DR.Apoptosis.Death deceiver.Nature,1998,396(6712):629-630.
98 Yang CR,Hsieh SL,Teng CM,Ho FM,Su WL,Lin WW.Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A,a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.Cancer Res,2004,64(3):1122-1129.
99 Yang CR,Wang JH,Hsieh SL,Wang SM,Hsu TL,Lin WW.Decoy receptor 3(DcR3)induces osteoclast formation from monocyte/macrophage lineage precursor cells.Cell Death Differ,2004,11(Suppl 1):S97-107.
100 Yang CR,Hsieh SL,Ho FM,Lin WW.Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1,VCAM-1,and IL-8 expression.J Immunol,2005,174(3):1647-1656.
101 Hsu TL,Wu YY,Chang YC,Yang CY,Lai MZ,Su WB,Hsieh SL.Attenuation of Th1 response in decoy receptor 3 transgenic mice.J Immunol,2005,175(8):5135-5145.
102 Chin D,Boyle GM,Kane AJ,Theile DR,Hayward NK,Parson PG,Coman WB.Invasion and metastasis markers in cancers.Br J Plast Surg,2005,58(4):466-474.
103 Sherbet GV,Patil D.Genetic abnormalities of cell proliferation,invasion and metastasis,with special reference to gynaecological cancers,Anticancer Res,2003,23(2B):1357-1371.
104 Herath NI,Leggett BA,MacDonald GA.Review of genetic and epigenetic alterations in hepatocarcinogenesis.J Gastroenterol Hepatol,2006,21(1 Pt 1):15-21.
105 Zhou XD.Recurrence and metastasis of hepatocellular carcinoma:progress and prospects.Hepatobiliary Pancreat Dis Int,2002,1(1):35-41.
106 Qin LX,Tang ZY.Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma:a review of the literature.J Cancer Res Clin Oncol,2004,130(9):497-513.
107 Sun B,Zhang S,Zhang D,Du J,Guo H,Zhao X,Zhang W,Hao X.Vasculogenic mimicry is associated with high tumor grade,invasion and metastasis,and short survival in patients with hepatocellular carcinoma.Oncol Rep,2006,16(4):693-698.
108 Pang R,Poon RT.Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.Cancer Lett,2006,242(2):151-167.
109 Zhang X,Zhang H,Ye L.Effects of hepatitis B virus X protein on the development of liver cancer.J Lab Clin Med,2006,147(2):58-66.
110 Cerny A,Chisari FV.Immunological aspects of HCV infection. Intervirology,1994,37(2):119-125.
111 Carillo MC,Alvarez Mde L,Quiroga AD.Interferon alfa-2b triggers transforming growth factor-beta-induced apoptosis on preneoplasticliver.Ann Hepatol,2006,5(4):244-250.
112 Alexia C,Fallot G,Lasfer M,Schweizer-Groyer G,Groyer A.An evaluation of the role of insulin-like growth factors(IGF)and of type-Ⅰ IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.Biochem Pharmacol,2004,68(6):1003-1015.
113 Lim TY,Cheong JY,Cho SW,Sim SJ,Kim JS,Choi SJ,Choi JW,Kwon HC,Lee KM,Kim JK,Won JH,Yoo BM,Lee KJ,Hahm KB,Kim JH.Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis.Korean J Hepatol,2006,12(1):65-73.
114 Parikh PM,Fuloria J,Babu G,Doval DC,Awasthy BS,Pai VR,Prabhakaran PS,Benson AB.A phase Ⅱ study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.Trop Gastroenterol,2005,26(3):115-118.
115 Park SH,Lee Y,Han SH,Kwon SY,Kwon OS,Kim SS,Kim JH,Park YH,Lee JN,Bang SM,Cho EK,Shin DB,Lee JH.Systemic chemotherapy with doxorubicin,cisplatin and capecitabine for metastatic hepatocellular carcinoma.BMC Cancer,2006,6:3.
116李玉龙,陈香宇,段芳龄.PD98059提高HBx~+HepG2对顺铂的敏感性.中华肝脏病杂志,2005,13(7):543-544.
117 Moravcova J,Brdicka R.Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR.Cas Lek Cesk,2005,144(1):32-37.
118 Tanke HJ,Dirks RW,Raap T.FISH and immunocytochemistry:towards visualising single target molecules in living cells.Curr Opin Biotechnol,2005,16(1):49-54.
119 Van Noorden S.Advances in immunocytochemistry.Folia Histochem Cytobiol,2002,40(2):121-124.
120 Fetsch PA,Abati A.Immunocytochemistry in effusion cytology:a contemporary review.Cancer,2001,93(5):293-308.
121 Oda E,Ohki R,Murasawa H,Nemoto J,Shibue T,Yamashita T,Tokino T,Taniguchi T,Tanaka N.Noxa,a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.Science,2000,288(5468):1053-1058.
122曲建慧,朱明华,文军慧,林静,李芳梅,倪灿荣.不同p53状态的肝癌细胞系DNA损伤修复能力的比较.肿瘤,2003,23(3):177-179.
123 Matsuhashi N,Saio M,Matsuo A,Sugiyama Y,Saji S.The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis:time- and p53 expression-dependency of anti-cancer drugs.Oncol Rep,2005,14(3):609-615.
124 Okamura M,Hashimoto K,Shimada J,Sakagami H.Apoptosis- inducing activity of cisplatin(CDDP)against human hepatoma and oral squamous cell carcinoma cell lines.Anticancer Res,2004,24(2B):655-661.
125 Marzano C,Gandin V,Folda A,Scutari G,Bindoli A,Rigobello MP.Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.Free Radio Biol Med,2007,42(6):872-881.
126 Yu W,Shun MC,Anderson K,Chen H,Sanders BG,Kline K.alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.Apoptosis,2006,11(10):1813-1823.
127 Surowiak P,Materna V,Maciejczyk A,Pudelko M,Markwitz E,Spaczynski M,Dietel M,Zabel M,Lage H.Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.Virchows Arch,2007,450(3):279-285.
128 Parikh PM,Fuloria J,Babu G,Doval DC,Awasthy BS,Pai VR,Prabhakaran PS,Benson AB.A phase Ⅱ study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.Trop Gastroenterol,2005,26(3):115-118.
129 Kreitman RJ.Immunotoxins for targeted cancer therapy.AAPS J,2006,8(3):E532-551.
1 Shen HM,Pervaiz S.TNF receptor superfamily-induced cell death:redox-dependent execution.FASEB J,2006,20(10):1589-1598.
2 Ashkenazi A,Dixit VM.Apoptosis control by death and decoy receptors.CurT Opin Cell Biol,1999,11(2):255-260.
3 Ashkenazi A.Targeting death and decoy receptors of the tumour-necrosis factor superfamily.Nat Rev Cancer,2002,2(6):420-430.
4 Yu KY,KwonB,Ni J,Zhai Y,Ebner R,Kwon BS.Anewly identified member of tumor necrosis factor receptor superfamily(TR6)suppresses LIGHT-mediated apoptosis.J Biol Chem,1999,274(20):13733-13736.Gill RM,Hunt JS.Soluble receptor(DcR3)and cellular inhibitor of apoptosis-2(cIAP-2)protect human cytotrophoblast cells against LIGHT-mediated apoptosis.Am J Pathol,2004,165(1):309-317.
6 Migone TS,Zhang J,Luo X,Zhuang L,Chen C,Hu B,Hong JS,Perry JW,Chen SF,Zhou JX,Cho YH,Ullrich S,Kanakaraj P,Carrell J,Boyd E,Olsen HS,Hu G,Pukac L,Liu D,Ni J,Kim S,Gentz R,Feng P,Moore PA,Ruben SM,Wei P.TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator,Immunity,2002,16(3):479-492.
7 Yang CR,Hsieh SL,Teng CM,Ho FM,Su WL,Lin WW.Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A,a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.Cancer Res,2004,64(3):1122-1129.
8 Simonet WS,Lacey DL,Dunstan CR,Kelley M,Chang MS,Luthy R,Nguyen HQ,Wooden S,Bennett L,Boone T,Shimamoto G, DeRoseM,Elliott R,Colombero A,Tan HL,Trail G,Sullivan J,Davy E,Bucay N,Renshaw-Gegg L,Hughes TM,Hill D,Pattison W,Campbell P,Sander S,VanG,Tarpley J,DerbyP,Lee R,Boyle WJ.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density.Cell,1997,89(2):309-319.
9 Onyia JE,Galvin RJ,Ma YL,Halladay DL,Miles RR,Yang X,Fuson T,Cain RL,Zeng QQ,Chandrasekhar S,Emkey R,Xu Y,Thirunavukkarasu K,Bryant HU,Martin TJ.Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.J Pharmacol Exp Ther,2004,309(1):369-379.
10 Degli-Esposti MA,Smolak PJ,Walczak H,Waugh J,Huang CP,DuBose RF,Goodwin RG,Smith CA.Cloning and characterization of TRAIL-R3,a novel member of the emerging TRAIL receptor family.J Exp Med,1997,186(7):1165-1170.
11 Ruiz de Almodovar C,Lopez-Rivas A,Redondo JM,Rodriguez A.Transcriptional regulation of the TRAIL-R3 gene.Vitam Horm,2004,67(1):51-63.
12 Smith CA,Davis T,Anderson D,Solam L,Beckmann MP,Jerzy R,Dower SK,Cosman D,Goodwin RG.A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.Science,1990,248(4958):1019-1023.
13 Idriss HT,Naismith JH.TNF alpha and the TNF receptor superfamily:structure-function relationship(s).Microsc Res Tech,2000,50(3):184-195.
14 Howard ST,Chan YS,Smith GL.Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family.Virology,1991,180(2):633-647.
15 Hu FQ,Smith CA,Pickup DJ.Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type Ⅱ TNF receptor.Virology,1994,204(1):343-356.
16 Brunetti CR,Paulose-Murphy M,Singh R,Qin J,Barrett JW,Tardivel A,Schneider P,Essani K,McFadden G.A secreted high-affinity inhibitor of human TNF from Tanapox virus.Proc Natl Acad Sci U S A,2003,100(8):4831-4836.
17 Gruss HJ,Dower SK.Tumor necrosis factor ligand superfamily:involvement in the pathology of malignant lymphomas.Blood,1995,85(12):3378-3404.
18 Goetz FW,Planas JV,MacKenzie S.Tumor necrosis factors.Dev Comp Immunol,2004,28(5):487-497.
19 Pitti RM,Marsters SA,Lawrence DA,Roy M,Kischkel FC,Dowd P,Huang A,Donahue CJ,Sherwood SW,Baldwin DT,Godowski PJ,Wood WI,Gurney AL,Hillan KJ,Cohen RL,Goddard AD,Botstein D,Ashkenazi A.Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.Nature,1998,396(6712):699-703.
20 Bai C,Connolly B,Metzker ML,Hilliard CA,Liu X,Sandig V,Soderman A,Galloway SM,Liu Q,Austin CP,Caskey CT.Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.Proc Natl Acad Sci U S A,2000,97(3):1230-1235.
21 Schwendel A,Richard F,Langreck H,Kaufmann O,Lage H,Winzer KJ,Petersen I,Dietel M.Chromosome alterations in breast carcinomas:frequent involvement of DNA losses including chromosomes 4q and 21q.Br J Cancer,1998,78(6):806-811.
22 Richard F,Pacyna-Gengelbach M,Schluns K,Fleige B,Winzer KJ,Szymas J,Dietel M,Petersen I,Schwendel A.Patterns of chromosomal imbalances in invasive breast cancer.Int J Cancer,2000,89(3):305-310.
23 Sakakura C,Mori T,Sakabe T,Ariyama Y,Shinomiya T,Date K, Hagiwara A, Yamaguchi T, Takahashi T, Nakamura Y, Abe T, Inazawa J. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer, 1999, 24(4):299-305.
24 Altura RA, Maris JM, Li H, Boyett JM, Brodeur GM, Look AT. Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. Genes Chromosomes Cancer, 1997, 19(3): 176-184.
25 Shinomiya T, Mori T, Ariyama Y, Sakabe T, Fukuda Y, Murakami Y, Nakamura Y, Inazawa J. Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer, 1999 , 24(4):337-344.
26 Fujita Y, Sakakura C, Shimomura K, Nakanishi M, Yasuoka R, Aragane H, Hagiwara A, Abe T, Inazawa J, Yamagishi H. Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology, 2003, 50(54): 1857-1863.
27 Wroblewski VJ, McCloud C, Davis K, Manetta J, Micanovic R, Witcher DR. Pharmacokinetics , metabolic stability , and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)] , in cynomolgus monkeys and mice. Drug Metab Dispos, 2003, 31(4):502-507.
28 Wroblewski VJ, Witcher DR, Becker GW, Davis KA, Dou S, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol, 2003, 65(4):657-667.
29 Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y,Hyodoh F,Ueki H,KusakaM,Kita S,Ueki A.Over-expression of the decoy receptor 3(DcR3)gene in peripheral blood mononuclear cells(PBMC)derived from silicosis patients.Clin Exp Immunol,2000,119(2):323-327.
30 Kim S,McAuliffe WJ,Zaritskaya LS,Moore PA,Zhang L,Nardelli B.Selective induction of tumor necrosis factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells.Infection and Immunity,2004,72(1):89-93.
31 Li H,Zhang L,Lou H,Ding I,Kim S,Wang L,Huang J,Di Sant'Agnese PA,Lei JY.Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.Am J Clin Pathol,2005,124(2):282-287.
32 Kim S,Fotiadu A,Kotoula V.Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.Clin Immunol,2005,115(3):286-294.
33 Maeda T,Hao C,Tron VA.Ultraviolet light(UV)regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes.J Cutan Med Surg,2001,5(4):294-298.
34 Wu Y,Han B,Sheng H,Lin M,Moore PA,Zhang J,Wu J.Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.Int J Cancer,2003,105(5):724-732.
35 陈罡,罗殿中.原发性肝细胞癌中诱捕受体3的过度表达及临床意义.广东医学,2006,27(10):1438-1440.
36 Takahama Y,Yamada Y,Emoto K,Fujimoto H,Takayama T,Ueno M,Uchida H,Hirao S,Mizuno T,Nakajima Y.The prognostic significance of overexpression of the decoy receptor for Fas ligand(DcR3)in patients with gastric carcinomas.Gastric Cancer,2002,5(2):61-68.
37 Elnemr A,Ohta T,Yachie A,Kayahara M,Kitagawa H,Fujimura T,Ninomiya I,Fushida S,Nishimura GI,Shimizu K,Miwa K.Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway.Int J Oncol,2001,18(2):311-316.
38 Ibrahim SM,Ringel J,Schmidt C,Ringel B,Muller P,Koczan D,Thiesen HJ,Lohr M.Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.Pancreas,2001,23(1):72-79.
39 Tsuji S,Hosotani R,Yonehara S,Masui T,Tulachan SS,Nakajima S,Kobayashi H,Koizumi M,Toyoda E,Ito D,Kami K,Mori T,Fujimoto K,Doi R,Imamura M.Endogenous decoy receptor 3blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.Int J Cancer,2003,106(1):17-25.
40 Roth W,Isenmann S,Nakamura M,Platten M,Wick W,Kleihues P,Bahr M,Ohgaki H,Ashkenazi A,Weller M.Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95ligand-induced apoptosis and chemotaxis.Cancer Res,2001,61(6):2759-2765.
41 Arakawa Y,Tachibana O,Hasegawa M,Miyamori T,Yamashita J,Hayashi Y.Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.Acta Neuropathol(Berl),2005,109(3):294-298.
42 Ohshima K,Haraoka S,Sugihara M,Suzumiya J,Kawasaki C,Kanda M,Kikuchi M.Amplification and expression of a decoy receptor for fas ligand(DcR3)in virus(EBV or HTLV-Ⅰ)associated lymphomas.Cancer Lett,2000,160(1):89-97.
43 Shen HW,Gao SL,Wu YL,Peng SY.Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.World J Gastroenterol,2005,11(38):5926-5930.
44吴育连,于俊秀,沈宏伟,韩冰,高顺良.血清TR6升高与胃癌淋巴转移分期的关系.中华外科杂志,2003,41(12):928-931.
45 Mild G,Bachmann F,Boulay JL,Glatz K,Laffer U,Lowy A,Metzger U,Reuter J,Terracciano L,Herrmann R,Rochlitz C.DcR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer,lnternational Journal of Cancer,2002,102(3):254-257.
46陈罡,罗殿中,王云,廖芝玲,张美艳.肝细胞癌中DcR3表达和癌细胞凋亡的关系研究.中华病理学杂志,2007,36(2):113-117.
47 Shi G,Wu Y,Zhang J,Wu J.Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo.J Immunol,2003,171(7):3407-3414.
48 Wan X,Shi G,Semenuk M,Zhang J,Wu J.DcR3/TR6 modulates immune cell interactions.Journal of cellular biochemistry,2003,89(3):603-612.
49 Chang YC,Hsu TL,Lin HH,Chio CC,Chiu AW,Chen NJ,Lin CH,Hsieh SL.Modulation of macrophage differentiation and activation by decoy receptor 3.Journal of leukocyte biology,2004,75(3):486-494.
50 Yang CR,Wang JH,Hsieh SL,Wang SM,Hsu TL,Lin WW.Decoy receptor 3(DcR3)induces osteoclast formation from monocyte/macrophage lineage precursor cells.Cell Death Differ,2004,11(Suppl 1):S97-107.
51 Yang CR,Hsieh SL,Teng CM,Ho FM,Su WL,Lin WW.Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A,a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.Cancer Res,2004,64(3):1122-1129.
52吴泰璜,段伟宏,苏忠学,吴亚光.反义DcR3 RNA转染诱导肝癌细胞凋亡的作用.中华微生物学和免疫学杂志,2005,25(10):799-802.
53段伟宏,苏忠学,吴泰璜.DcR3反义RNA与顺铂对肝癌细胞凋亡影响的比较。中国现代普通外科进展,2005,8(2):90-92.
54 Takahashi T,Tanaka M,Inazawa J,Abe T,Suda T,Nagata S.Human Fas ligand:gene structure,chromosomal location and species specificity,Int Immunol,1994,6(10):1567-1574.
55 Ju ST,Panka DJ,Cui H,Ettinger R,el-Khatib M,Sherr DH,Stanger BZ,Marshak-Rothstein A.Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.Nature,1995,373(6513):444-448.
56 Gajate C,Fonteriz RI,Cabaner C,Alvarez-Noves G,Alvarez-Rodriguez Y,Modolell M,Mollinedo F.Intracellular triggering of Fas,independently of FasL,as a new mechanism of antitumor ether lipid-induced apoptosis,lnt J Cancer,2000,85(5):674-682.
57 Gajate C,Del Canto-Janez E,Acuna AU,Amat-Guerri F,Geijo E,Santos-Beneit AM,Veldman RJ,Mollinedo F.Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.J Exp Med,2004,200(3):353-365.
58 Gajate C,Mollinedo F.The antitumor ether lipid ET-18-OCH(3)induces apoptosis through translocation and capping of Fas/CD95into membrane rafts in human leukemic cells.Blood,2001,98(13):3860-3863.
59 Kusakabe K,Otsuki Y,Kiso Y.Involvement of the fas ligand and fas system in apoptosis induction of mouse uterine natural killer cells.J Reprod Dev,2005,51(3):333-340.
60 Smyth MJ,Cretney E,Kelly JM,Westwood JA,Street SE,Yagita H,Takeda K,van Dommelen SL,Degli-Esposti MA,Hayakawa Y.Activation of NK cell cytotoxicity.Mol Immunol,2005,42(4):501-510.
61 Pinkoski MJ,Brunner T,Green DR,Lin T.Fas and Fas ligand in gut and liver.Am J Physiol Gastrointest Liver Physiol,2000,278(3):354-366.
62 Suda T,Okazaki T,Naito Y,Yokota T,Arai N,Ozaki S,Nakao K,Nagata S.Expression of the Fas ligand in cells of T cell lineage.J Immunol,1995,154(8):3806-3813.
63 Siegel RM,Chan FK,Chun HJ,Lenardo MJ.The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.Nat Immunol,2000,1(6):469-474.
64 Zaks TZ,Chappell DB,Rosenberg SA,Restifo NP.Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor:selective rescue by caspase inhibition.J Immunol,1999,162(6):3273-3279.
65 Karas M,Zaks TZ,Yakar S,Dudley ME,LeRoith D.TCR stimulation protects CD_8~+T cells from CD95 mediated apoptosis.Hum Immunol,2001,62(1):32-38.
66 Wahlsten JL,Gitchell HL,Chan CC,Wiggert B,Caspi RR.Fas and Fas ligand expressed on cells of the immune system,not on the target tissue,control induction of experimental autoimmune uveitis.J Immunol,2000,165(10):5480-5486.
67 Beyaert R,Van Loo G,Heyninck K,Vandenabeele P.Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas.Int Rev Cytol,2002,214(1):225-272.
68 Sheikh MS,Fornace AJ Jr.Death and decoy receptors and p53-mediated apoptosis.Leukemia,2000,14(8):1509-1513.
69 Zhang J,Salcedo TW,Wan X,Ullrich S,Hu B,Gregorio T,Feng P,Qi S,Chen H,Cho YH,Li Y,Moore PA,Wu J.Modulation of T-cell responses to alloantigens by TR6/DcR3.J Clin Invest,2001,107(11):1459-1468.
70 Hayashi S,Miura Y,Nishiyama T,Mitani M,Tateishi K,Sakai Y,Hashiramoto A,Kurosaka M,Shiozawa S,Doita M.Decoy receptor 3 expressedin rheumatoid synovial fibroblasts protects the cells against fas-induced apoptosis.Arthritis Rheum,2007,56(4):1067-1075.
71 ConnollyK,Cho YH,Duan R,Fikes J,Gregorio T,LaFleur DW,Okoye Z,Salcedo TW,Santiago G,Ullrich S,Wei P,Windle K,Wong E,Yao XT,Zhang YQ,Zheng G,Moore PA.In vivo inhibition of Fas ligand-mediated killing by TR6,a Fas ligand decoy receptor.J Pharmacol Exp Ther,2001,298(1):25-33.
72 Wortinger MA,Foley JW,Larocque P,Witcher DR,Lahn M,Jakubowski JA,Glasebrook A,SongHY.Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3analogue.Immunology,2003,110(2):225-233.
73 Mauri DN,Ebner R,Montgomery RI,Kochel KD,Cheung TC,Yu GL,Ruben S,Murphy M,Eisenberg RJ,Cohen GH,Spear PG,Ware CF.LIGHT,a new member of the TNF superfamily,and lymphotoxin alpha are ligands for herpesvirus entry mediator.Immunity,1998,8(1):21-30.
74 Gill RM,Ni J,Hunt JS.Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.Am J Pathol,2002,161(6):2011-2017.
75 Wan X,Zhang J,Luo H,Shi G,Kapnik E,Kim S,Kanakaraj P,Wu J.A TNF family member LIGHT transduces costimulatory signals into human T cells.J Immunol,2002,169(12):6813-6821.
76 Ware CF.Network communications:lymphotoxins,LIGHT,and TNF.Annu Rev Immunol.2005,23:787-819.
77 Morel Y,Truneh A,Costello RT,Olive D.LIGHT,a new TNF superfamily member,is essential for memory T helper cell-mediated activation of dendritic cells.Eur J Immunol,2003,33(11):3213-3219.
78 Yang D,Zhai Y,Zhang M.LIGHT,a new member of the TNF superfamily.J Biol Regul Homeost Agents,2002,16(3):206-210.
79 Chang YH,Hsieh SL,Chao Y,Chou YC,Lin WW.Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.J Biomed Sci,2005,12(2):363-3?5.
80 Bamias G,Martin C 3rd,Marini M,Hoang S,Mishina M,Ross WG,Sachedina MA,Friel CM,Mize J,Bickston SJ,Pizarro TT,Wei P,Cominelli F.Expression,localization,and functional activity of TLIA,a novel Th1-polarizing cytokine in inflammatory bowel disease.J Immunol,2003,171(9):4868-4874.
81 Wen L,Zhuang L,Luo X,Wei P.TLiA-inducedNF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1cells.J Biol Chem,2003,278(40):39251-39258.
82 Green DR.Apoptosis.Death deceiver.Nature,1998,396(6712):629-630.
83 Wu YY,Chang YC,Hsu TL,Hsieh SL,Lai MZ.Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.The Journal of Biological Chemistry,2004,279(42):44211 -44218.
84 Shi G,Luo H,Wan X,Salcedo TW,Zhang J,Wu J.Mouse T cells receive costimulatory signals from LIGHT,a TNF family member.Blood,2002,100(9):3279-3286.
85 Hsu MJ,Lin WW,Tsao WC,Chang YC,Hsu TL,Chiu AW,Chio CC,Hsieh SL.Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3.Experimental Cell Research,2004,292(2):241-251.
86 Hsu TL,Chang YC,Chen SJ,Liu YJ,Chiu AW,Chio CC,Chen L,Hsieh SL.Modulation of dendritic cell differentiation and maturation by decoy receptor 3.Journal of Immunology,2002,168(10):4846-4853.
87 Yang CR,Hsieh SL,Ho FM,Lin WW.Decoy receptor increases monocyte adhesion to endothelial cells via NF-κB-dependent up-regulation of intercellular adhesion molecule-1,VCAM-1,and IL-8expression.Journal of Immunology,2005,174(3):1647-1656.
88 Hwang SL,Lin CL,Cheng CY,LinFA,Lieu AS,Howng SL,Lee KS.Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery.Kaohsiung J Med Sci,2004,20(3):124-127.
89 Shi G,Mao J,Yu G,Zhang J,Wu J.Tumor vaccine based on cell surface expression of DcR3/TR6.Journal of Immunology,2005,174(8):4727-4735.
90 Wu SF,Liu TM,Lin YC,Sytwu HK,Juan HP,Chen ST,Shen KL,Hsi SC,Hsieh SL.Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice:from regulatory mechanism to clinical implication.Journal of Biology,2004,75(2):293-306.
91 Wu Y,Han B,Luo H,Roduit R,Salcedo TW,Moore PA,Zhang J,Wu J.DcR3/TR6 effectively prevent islet primary nonfunction after transplantation.Diabetes,2003,52(9):2279-2286.
92 Sung HH,Juang JH,Lin YC,Kuo CH,Hung JT,Chen A,Chang DM,Chang SY,Hsieh SL,Sytwu HK.Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice.The Journal of Experimental Medicine,2004,199(8):1143-1151.
2 Bai C,ConnollyB,MetzkerML,Hilliard CA,Liu X,Sandig V,Soderman A,Galloway SM,Liu Q,Austin CP,Caskey CT.Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.Proc Natl Acad Sci U S A,2000,97(3):1230-1235.
3 Schwendel A,Richard F,Langreck H,Kaufmann O,Lage H,Winzer KJ,Petersen I,Dietel M.Chromosome alterations in breast carcinomas:frequent involvement of DNA losses including chromosomes 4q and 21q.Br J Cancer,1998,78(6):806-811.
4 Sakakura C,Mori T,Sakabe T,Ariyama Y,Shinomiya T,Date K,HagiwaraA,Yamaguchi T,Takahashi T,Nakamura Y,Abe T,Inazawa J.Gains,losses,and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization.Genes Chromosomes Cancer,1999,24(4):299-305.
5 Muleris M,AlmeidaA,Gerbault-Seureau M,Malfoy B,Dutrillaux B.Identification of amplified DNA sequences in breast cancer and their organization within homogeneously staining regions.Genes Chromosomes Cancer,1995,14(3):155-163.
6 Altura RA,Maris JM,Li H,Boyett JM,Brodeur GM,Look AT.Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization.Genes Chromosomes Cancer,1997,19(3):176-184.
7 ShinomiyaT, Mori T, AriyamaY, Sakabe T, FukudaY, Murakami Y, Nakamura Y, Inazawa J. Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer, 1999, 24(4):337-344.
8 Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y. The prognostic significance of Overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer, 2002, 5 (2): 61-68.
9 Jinguo Chen, Lurong Zhang, Sunghee Kim. Quantification and detection of DcR3, a decoy receptor in TNFR family. Journal of Immunological Methods, 285 (2004): 63-70.
10 Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.Int J Cancer, 2003, 105(5):724-732.
11 Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, Rochlitz C. DcR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer. International Journal of Cancer, 2002, 102(3): 254-257.
12 Roth W, Isenmann S, Nakamura M, Platten M, Wick W, Kleihues P, Bahr M, Ohgaki H, Ashkenazi A, Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res, 2001, 61 (6): 2759-2765.
13 Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J, Hayashi Y. Frequent gene amplification and Overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol (Berl), 2005 , 109 (3) :294-298.
14 Ohshima K,Haraoka S,Sugihara M,Suzumiya J,Kawasaki C,Kanda M,Kikuchi M.Amplification and expression of a decoy receptor for fas ligand(DcR3)in virus(EBV or HTLV-Ⅰ)associated lymphomas.Cancer Lett,2000,160(1):89-97.
15 Elnemr A,OhtaT,Yachie A,KayaharaM,KitagawaH,Fujimura T,Ninomiya I,Fushida S,Nishimura GI,Shimizu K,Miwa K.Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway.Int J Oncol,2001,18(2):311-316.
16 IbrahimSM,Ringel J,Schmidt C,Ringel B,MullerP,Koczan D,Thiesen HJ,Lohr M.Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.Pancreas,2001,23(1):72-79.
17 Tsuji S,Hosotani R,Yonehara S,Masui T,Tulachan SS,Nakajima S,Kobayashi H,Koizumi M,Toyoda E,Ito D,Kami K,Mori T,Fujimoto K,Doi R,Imamura M.Endogenous decoy receptor 3blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma,lnt J Cancer,2003,106(1):17-25.
18 Li H,Zhang L,Lou H,Ding I,Kim S,Wang L,Huang J,Di Sant'Agnese PA,Lei JY.Over-expression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.Am J Clin Pathol,2005,124(2):282-287.
19 Shen HW,Gao SL,Wu YL,Peng SY.Over-expression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.World J Gastroenterol,2005,11(38):5926-5930.
20 Yu KY,Kwon B,Ni J,Zhai Y,Ebner R,Kwon BS.A newly identified member of tumor necrosis factor receptor superfamily(TR6) suppresses LIGHT-mediated apoptosis.J Biol Chem,1999,274(20):13733-13736.
21 Maeda T,Hao C,Tron VA.Ultraviolet light(UV)regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes.J Cutan Med Surg,2001,5(4):294-298.
22 Edmondson HA,Steiner PE.Primary carcinoma of the liver:a study of 100 cases among 48,900 necropsies.Cancer,1954,7(3):462-503.
23 Tanaka S,Noguchi N,Ochiai T,Kudo A,Nakamura N,Ito K,Kawamura T,Teramoto K,Arii S.Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria:rationale for partial hepatectomy as first strategy.J Am Coll Surg,2007,204(1):1-6.
24 Tanaka H,Kubo S,TsukamotoT,ShutoT,Takemura S,Yamamoto T,Okuda T,Kanazawa A,Hirohashi K.Recurrence rate and transplantability after liver resection in patients with hepatocellular carcinoma who initially met transplantation criteria.Transplant Proc,2005,37(2):1254-1256.
25王毅军,杜智,吴尘轩,袁强,舒桂明,张淑萍.切缘冷冻对原发性肝癌切除术后局部复发的预防作用.中华普通外科杂志,2006,21(6):438-440.
26 Tang SH,Yang DH,Huang W,Zhou M,Zhou HK,Lu XH,Ye G.Differential promoter usage for insulin-like growth factor-Ⅱ gene in Chinese hepatocellular carcinoma with hepatitis B virus infection.Cancer Detect Prey,2006,30(2):192-203.
27白伟良,任重,潘子民,高红.KAI1基因在喉鳞癌中的表达及其临床意义.中华肿瘤杂志,2005,27(5):289-291.
28孙现军,左文述,马恒,侯文红,蔡淑萍,姜希宏.骨桥蛋白mRNA在胃癌中的表达及其临床意义.中华肿瘤杂志,2005,27(5):292-295.
29 Saiki RK,Scharf S,Faloona F,Mullis KB,Horn GT,Erlich HA,Arnheim N.Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.Science,1985,230(4732):1350-1354.
30吴育连,于俊秀,沈宏伟,韩冰,高顺良.血清TR6升高与胃癌淋巴转移分期的关系.中华外科杂志,2003,41(12):928-931.
31 Hwang SL,LinCL,Cheng CY,Lin FA,Lieu AS,Howng SL,Lee KS.Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery.Kaohsiung J Med Sci,2004,20(3):124-127.
32 Shi G,Mao J,Yu G,Zhang J,Wu J.Tumor vaccine based on cell surface expression of DcR3/TR6.Journal of Immunology,2005,174(8):4727-4735.
33 Wu YY,Chang YC,Hsu TL,Hsieh SL,Lai MZ.Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.The Journal of Biological Chemistry,2004,279(42):44211-44218.
34段伟宏,苏忠学,吴泰璜.DcR3反义RNA与顺铂对肝癌细胞凋亡影响的比较.中国现代普通外科进展,2005,8(2):90-92.
35 Ashkenazi A.Targeting death and decoy receptors of the tumour-necrosis factor superfamily.Nat Rev Cancer,2002,2(6):420-430.
36 Chang YC,Chan gu,Jackson DG,Hsieh SL.The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion.J Immunol,2006,176(1):173-180.
37 Yachnis AT,Trojanowski JQ.Studies of childhood brain tumors using immunohistochemistry and microwave technology:methodological considerations.J Neurosci Methods,1994,55(2):191-200.
38 Almqvist PM,Mah R,Lendahl U,Jacobsson B,Hendson G.Immunohistochemical detection of nestin in pediatric brain tumors.J Histochem Cytochem,2002,50(2):147-158.
39陈罡,罗殿中,李萍,王华.改进免疫组织化学SP法的探讨.广西医科大学学报,2005,22(1):138-139.
40 Watanabe A,Cornelison R,Hostetter G.Tissue microarrays:applications in genomic research.Expert Rev Mol Diagn,2005,5(2):171-181.
41 Rimm DL,Camp RL,Charette LA,Costa J,Olsen DA,Reiss M.Tissue microarray:a new technology for amplification of tissue resources.Cancer J,2001,7(1):24-31.
42 Donati V,Faviana P,Dell'omodarme M,Prati MC,Camacci T,De IesoK,Giannini R,Lucchi M,Mussi A,Pingitore R,Basolo F,Fontanini G.Applications of tissue microarray technology in immunohistochemistry:a study on c-kit expression in small cell lung cancer.Hum Pathol,2004,35(11):1347-1352.
43 Kononen J,Bubendorf L,Kallioniemi A,Barlund M,Schraml P,Leighton S,Torhorst J,Mihatsch MJ,Sauter G,Kallioniemi OP.Tissue microarray for high-throughput molecular profiling of tumor specimens.Nat Med,1998,4(7):844-847.
44李锦军,葛超,万大方,顾健人.高通量肿瘤组织-细胞系芯片技术平台的建立及应用.中华病理学杂志,2002,31(5):461-463.
45陈莉,李德春,朱远源.NET-1蛋白表达与肝癌临床病理因素相关性探讨,中华病理学杂志,2005,34(9):596-597.
46 Horvath L,Henshall S.The application of tissue microarrays to cancer research.Pathology,2001,33(2):125-129.
47 Shergill IS,Shergill NK,Arya M,Patel HR.Tissue microarrays:a current medical research tool.Curr Med Res Opin,2004,20(5):707-712.
48 Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer.Breast Cancer Res Treat,2004,85(1):13-22.
49 Hoos A,Nissan A,Stojadinovic A,Shia J,Hedvat CV,Leung DH,Paty PB,Klimstra D,Cordon-Cardo C,Wong WD.Tissue microarray molecular profiling of early,node-negative adenocarcinoma of the rectum: a comprehensive analysis. Clin Cancer Res, 2002, 8(12): 3841-3849.
50 Mucci NR, Akdas G, ManelyS, Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. Hum Pathol, 2000, 31 (4): 406-414.
51 MochH, KononenT, Kallioniemi OP, Sauter G. Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol, 2001, 8(1): 14-20.
52 West RB, van de Rijn M. The role of microarray technologies in the study of soft tissue tumours. Histopathology , 2006, 48(1) :22-31.
53 Hewitt SM. The application of tissue microarrays in the validation of microarray results. Methods Enzymol. 2006; 410(1):400—415.
54 Simon R, Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol, 2002, 30(12): 1365-1372.
55 Kim S, Fotiadu A, Kotoula V. Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia. Clin Immunol, 2005, 115(3): 286-294.
56 Fevery J. Non-surgical treatment of hepatocellular carcinoma (HCC).Acta Gastroenterol Belg, 2000 , 63(2) :233-235.
57 Sturm JW, Keese M. Multimodal treatment of hepatocellular carcinoma (HCC). Onkologie, 2004, 27(3):294-303.
58 Shi G, LuoH, Wan X, Salcedo TW, Zhang J, Wu J. Mouse T cells receive costimulatory signals from LIGHT , a TNF family member. Blood, 2002, 100(9):3279-3286.
59 Wroblewski VJ, WitcherDR, Becker GW, Davis KA, DouS, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIOHr.Biochem Pharmacol,2003,65(4):657-667.
60 Ideker T,Thorsson V,Ranish SA,Christmas R,Buhler J,Eng JK,Bumgarner R,Goodlett DR,Aebersold R,Hood L.Integrated genomic and proteomic analyses of a systematically perturbed metabolic network.Science,2001,292(5518):929-934.
61 Kerr JF,Wyllie AH,Currie AR.Apoptosis:a basic biological phenomenon with wide-ranging implications in tissue kinetics.Br J Cancer,1972,26(4):239-257.
62 Soria Gonzalez JE,Orea Solano M.Apoptosis.Rev Alerg Mex,2002,49(4):121-128.
63 Thompsin CB.Apoptosis in pathogenesis and treatment of disease.Science,1995,267(5302):1456-1462.
64郑建勇,李开宗,王为忠.肝癌组织中p27基因的表达及其与细胞凋亡的关系.世界华人消化杂志,2002,10(2):883-886.
65 Takahashi T,Tanaka M,Inazawa J,Abe T,Suda T,Nagata S.Human Fas ligand:gene structure,chromosomal location and species specificity.Int Immunol,1994,6(10):1567-1574.
66 Ju ST,Panka DJ,Cui H,Ettinger R,el-Khatib M,Sherr DH,Stanger BZ,Marshak-Rothstein A.Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.Nature,1995,373(6513):444-448.
67 Gajate C,Fonteriz RI,Cabaner C,Alvarez-Noves G,Alvarez-Rodriguez Y,Modolell M,Mollinedo F.Intracellular triggering of Fas,independently of FasL,as a new mechanism of antitumor ether lipid-induced apoptosis,lnt J Cancer,2000,85(5):674-682.
68 Gajate C,Del Canto-Janez E,Acuna AU,Amat-Guerri F,Geijo E,Santos-Beneit AM,Veldman RJ,Mollinedo F.Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.J Exp Med,2004,200(3):353-365.
69 Gajate C,Mollinedo F.The antitumor ether lipid ET-18-OCH(3)induces apoptosis through translocation and capping of Fas/CD95into membrane rafts in human leukemic cells.Blood,2001,98(13):3860-3863.
70 Kusakabe K,Otsuki Y,Kiso Y.Involvement of the fas ligand and fas system in apoptosis induction of mouse uterine natural killer cells.J Reprod Dev,2005,51(3):333-340.
71 Smyth MJ,Cretney E,Kelly JM,Westwood JA,Street SE,Yagita H,Takeda K,van Dommelen SL,Uegli-Esposti MA,Hayakawa Y.Activation of NK cell cytotoxicity.Mol Immunol,2005,42(4):501-510.
72 Pinkoski MJ,Brunner T,Green DR,Lin T.Fas and Fas ligand in gut and liver.Am J Physiol Gastrointest Liver Physiol,2000,278(3):354-366.
73 Suda T,Okazaki T,Naito Y,Yokota T,Arai N,Ozaki S,Nakao K,Nagata S.Expression of the Fas ligand in cells of T cell lineage.J Immunol,1995,154(8):3806-3813.
74 Siegel RM,Chan FK,Chun HJ,Lenardo MJ.The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.Nat Immunol,2000,1(6):469-474.
75 Zaks TZ,Chappell DB,Rosenberg SA,Restifo NP.Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor:selective rescue by caspase inhibition.J Immunol,1999,162(6):3273-3279.
76 Karas M,Zaks TZ,Yakar S,Dudley ME,LeRoith D.TCR stimulation protects CD8+T cells from CD95 mediated apoptosis.Hum Immunol,2001,62(1):32-38.
77 Wahlsten JL,Gitchell HL,Chan CC,Wiggert B,Caspi RR.Fas and Fas ligand expressed on cells of the immune system,not on the target tissue,control induction of experimental autoimmune uveitis.J Immunol,2000,165(10):5480-5486.
78 Beyaert R,Van Loo G,Heyninck K,Vandenabeele P.Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas.Int Rev Cytol,2002,214(1):225-272.
79 Sheikh MS,Fornace AJ Jr.Death and decoy receptors and p53-mediated apoptosis.Leukemia,2000,14(8):1509-1513.
80 Zhang J,Salcedo TW,Wan X,Ullrich S,Hu B,Gregorio T,Feng P,Qi S,Chen H,Cho YH,Li Y,Moore PA,Wu J.Modulation of T-cell responses to alloantigens by TR6/DcR3.J Clin Invest,2001,107(11):1459-1468.
81 Hayashi S,Miura Y,Nishiyama T,Mitani M,Tateishi K,Sakai Y,Hashiramoto A,Kurosaka M,Shiozawa S,Doita M.Decoy receptor 3expressed in rheumatoid synovial fibroblasts protects the cells against fas-induced apoptosis.Arthritis Rheum,2007,56(4):1067-1075.
82 Connolly K,Cho YH,Duan R,Fikes J,Gregorio T,LaFleur DW,Okoye Z,Salcedo TW,Santiago G,Ullrich S,Wei P,Windle K,Wong E,Yao XT,Zhang YQ,Zheng G,Moore PA.In vivo inhibition of Fas ligand-mediated killing by TR6,a Fas ligand decoy receptor.J Pharmacol Exp Ther,2001,298(1):25-33.
83 Wortinger MA,Foley JW,Larocque P,Witcher DR,Lahn M,Jakubowski JA,Glasebrook A,Song HY.Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3analogue,Immunology,2003,110(2):225-233.
84 Mauri DN,Ebner R,Montgomery RI,Kochel KD,Cheung TC,Yu GL,Ruben S,Murphy M,Eisenberg RJ,Cohen GH,Spear PG,Ware CF.LIGHT,a new member of the TNF superfamily,and lymphotoxin alpha are ligands for herpesvirus entry mediator.Immunity,1998, 8(1):21-30.
85 Gill RM,Ni J,Hunt JS.Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.Am J Pathol,2002,161(6):2011-2017.
86 Gill RM,Hunt JS.Soluble receptor(DcR3)and cellular inhibitor of apoptosis-2(cIAP-2)protect human cytotrophoblast cells against LIGHT-mediated apoptosis.Am J Pathol,2004,165(1):309-317.
87 Wan X,Zhang J,Luo H,Shi G,Kapnik E,Kim S,Kanakaraj P,Wu J.A TNF family member LIGHT transduces costimulatory signals into human T cells.J Immunol,2002,169(12):6813-6821.
88 Ware CF.Network communications:lymphotoxins,LIGHT,and TNF.Annu Rev Immunol.2005,23:787-819.
89 Morel Y,Truneh A,Costello RT,Olive D.LIGHT,a new TNF superfamily member,is essential for memory T helper cell-mediated activation of dendritic cells.Eur J Immunol,2003,33(11):3213-3219.
90 Yang D,Zhai Y,Zhang M.LIGHT,a new member of the TNF superfamily.J Biol Regul Homeost Agents,2OO2,16(3):2O6-210.
91 Chang YH,Hsieh SL,Chao Y,Chou YC,Lin WW.Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.J Biomed Sci,2005,12(2):363-375.
92 Chen MC,Hwang MJ,Chou YC,Chen WH,Cheng G,Nakano H,Luh TY,Mai SC,Hsieh SL.The role of apoptosis signal-regulating kinase 1 in lymphotoxin-beta receptor-mediated cell death.J Biol Chem,2003,278(18):16073-16081.
93 Scheu S,Alferink J,Potzel T,Barchet W,Kalinke U,Pfeffer K.Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis.J Exp Med,2002,195(12):1613-1624.
94 Migone TS,Zhang J,Luo X,Zhuang L,Chen C,Hu B,Hong JS,Perry JW,Chen SF,Zhou JX,Cho YH,Ullrich S,Kanakaraj P,Carrell J,Boyd E,Olsen HS,Hu G,Pukac L,Liu D,Ni J,Kim S,Gentz R,Feng P,Moore PA,Ruben SM,Wei P.TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator.Immunity,2002,16(3):479-492.
95 Bamias G,Martin C 3rd,Marini M,Hoang S,Mishina M,Ross WG,Sachedina Mf,Friel CM,Mize J,Bickston SJ,Pizarro TT,Wei P,Cominelli F.Expression,localization,and functional activity of TL1A,a novel Th1-polarizing cytokine in inflammatory bowel disease.J Immunol,2003,171(9):4868-4874.
96 Wen L,Zhuang L,Luo X,Wei P.TL1A-induced NF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1cells.J Biol Chem,2003,278(40):39251-39258.
97 Green DR.Apoptosis.Death deceiver.Nature,1998,396(6712):629-630.
98 Yang CR,Hsieh SL,Teng CM,Ho FM,Su WL,Lin WW.Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A,a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.Cancer Res,2004,64(3):1122-1129.
99 Yang CR,Wang JH,Hsieh SL,Wang SM,Hsu TL,Lin WW.Decoy receptor 3(DcR3)induces osteoclast formation from monocyte/macrophage lineage precursor cells.Cell Death Differ,2004,11(Suppl 1):S97-107.
100 Yang CR,Hsieh SL,Ho FM,Lin WW.Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1,VCAM-1,and IL-8 expression.J Immunol,2005,174(3):1647-1656.
101 Hsu TL,Wu YY,Chang YC,Yang CY,Lai MZ,Su WB,Hsieh SL.Attenuation of Th1 response in decoy receptor 3 transgenic mice.J Immunol,2005,175(8):5135-5145.
102 Chin D,Boyle GM,Kane AJ,Theile DR,Hayward NK,Parson PG,Coman WB.Invasion and metastasis markers in cancers.Br J Plast Surg,2005,58(4):466-474.
103 Sherbet GV,Patil D.Genetic abnormalities of cell proliferation,invasion and metastasis,with special reference to gynaecological cancers,Anticancer Res,2003,23(2B):1357-1371.
104 Herath NI,Leggett BA,MacDonald GA.Review of genetic and epigenetic alterations in hepatocarcinogenesis.J Gastroenterol Hepatol,2006,21(1 Pt 1):15-21.
105 Zhou XD.Recurrence and metastasis of hepatocellular carcinoma:progress and prospects.Hepatobiliary Pancreat Dis Int,2002,1(1):35-41.
106 Qin LX,Tang ZY.Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma:a review of the literature.J Cancer Res Clin Oncol,2004,130(9):497-513.
107 Sun B,Zhang S,Zhang D,Du J,Guo H,Zhao X,Zhang W,Hao X.Vasculogenic mimicry is associated with high tumor grade,invasion and metastasis,and short survival in patients with hepatocellular carcinoma.Oncol Rep,2006,16(4):693-698.
108 Pang R,Poon RT.Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.Cancer Lett,2006,242(2):151-167.
109 Zhang X,Zhang H,Ye L.Effects of hepatitis B virus X protein on the development of liver cancer.J Lab Clin Med,2006,147(2):58-66.
110 Cerny A,Chisari FV.Immunological aspects of HCV infection. Intervirology,1994,37(2):119-125.
111 Carillo MC,Alvarez Mde L,Quiroga AD.Interferon alfa-2b triggers transforming growth factor-beta-induced apoptosis on preneoplasticliver.Ann Hepatol,2006,5(4):244-250.
112 Alexia C,Fallot G,Lasfer M,Schweizer-Groyer G,Groyer A.An evaluation of the role of insulin-like growth factors(IGF)and of type-Ⅰ IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis.Biochem Pharmacol,2004,68(6):1003-1015.
113 Lim TY,Cheong JY,Cho SW,Sim SJ,Kim JS,Choi SJ,Choi JW,Kwon HC,Lee KM,Kim JK,Won JH,Yoo BM,Lee KJ,Hahm KB,Kim JH.Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis.Korean J Hepatol,2006,12(1):65-73.
114 Parikh PM,Fuloria J,Babu G,Doval DC,Awasthy BS,Pai VR,Prabhakaran PS,Benson AB.A phase Ⅱ study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.Trop Gastroenterol,2005,26(3):115-118.
115 Park SH,Lee Y,Han SH,Kwon SY,Kwon OS,Kim SS,Kim JH,Park YH,Lee JN,Bang SM,Cho EK,Shin DB,Lee JH.Systemic chemotherapy with doxorubicin,cisplatin and capecitabine for metastatic hepatocellular carcinoma.BMC Cancer,2006,6:3.
116李玉龙,陈香宇,段芳龄.PD98059提高HBx~+HepG2对顺铂的敏感性.中华肝脏病杂志,2005,13(7):543-544.
117 Moravcova J,Brdicka R.Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR.Cas Lek Cesk,2005,144(1):32-37.
118 Tanke HJ,Dirks RW,Raap T.FISH and immunocytochemistry:towards visualising single target molecules in living cells.Curr Opin Biotechnol,2005,16(1):49-54.
119 Van Noorden S.Advances in immunocytochemistry.Folia Histochem Cytobiol,2002,40(2):121-124.
120 Fetsch PA,Abati A.Immunocytochemistry in effusion cytology:a contemporary review.Cancer,2001,93(5):293-308.
121 Oda E,Ohki R,Murasawa H,Nemoto J,Shibue T,Yamashita T,Tokino T,Taniguchi T,Tanaka N.Noxa,a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis.Science,2000,288(5468):1053-1058.
122曲建慧,朱明华,文军慧,林静,李芳梅,倪灿荣.不同p53状态的肝癌细胞系DNA损伤修复能力的比较.肿瘤,2003,23(3):177-179.
123 Matsuhashi N,Saio M,Matsuo A,Sugiyama Y,Saji S.The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis:time- and p53 expression-dependency of anti-cancer drugs.Oncol Rep,2005,14(3):609-615.
124 Okamura M,Hashimoto K,Shimada J,Sakagami H.Apoptosis- inducing activity of cisplatin(CDDP)against human hepatoma and oral squamous cell carcinoma cell lines.Anticancer Res,2004,24(2B):655-661.
125 Marzano C,Gandin V,Folda A,Scutari G,Bindoli A,Rigobello MP.Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.Free Radio Biol Med,2007,42(6):872-881.
126 Yu W,Shun MC,Anderson K,Chen H,Sanders BG,Kline K.alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.Apoptosis,2006,11(10):1813-1823.
127 Surowiak P,Materna V,Maciejczyk A,Pudelko M,Markwitz E,Spaczynski M,Dietel M,Zabel M,Lage H.Nuclear metallothionein expression correlates with cisplatin resistance of ovarian cancer cells and poor clinical outcome.Virchows Arch,2007,450(3):279-285.
128 Parikh PM,Fuloria J,Babu G,Doval DC,Awasthy BS,Pai VR,Prabhakaran PS,Benson AB.A phase Ⅱ study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.Trop Gastroenterol,2005,26(3):115-118.
129 Kreitman RJ.Immunotoxins for targeted cancer therapy.AAPS J,2006,8(3):E532-551.
1 Shen HM,Pervaiz S.TNF receptor superfamily-induced cell death:redox-dependent execution.FASEB J,2006,20(10):1589-1598.
2 Ashkenazi A,Dixit VM.Apoptosis control by death and decoy receptors.CurT Opin Cell Biol,1999,11(2):255-260.
3 Ashkenazi A.Targeting death and decoy receptors of the tumour-necrosis factor superfamily.Nat Rev Cancer,2002,2(6):420-430.
4 Yu KY,KwonB,Ni J,Zhai Y,Ebner R,Kwon BS.Anewly identified member of tumor necrosis factor receptor superfamily(TR6)suppresses LIGHT-mediated apoptosis.J Biol Chem,1999,274(20):13733-13736.Gill RM,Hunt JS.Soluble receptor(DcR3)and cellular inhibitor of apoptosis-2(cIAP-2)protect human cytotrophoblast cells against LIGHT-mediated apoptosis.Am J Pathol,2004,165(1):309-317.
6 Migone TS,Zhang J,Luo X,Zhuang L,Chen C,Hu B,Hong JS,Perry JW,Chen SF,Zhou JX,Cho YH,Ullrich S,Kanakaraj P,Carrell J,Boyd E,Olsen HS,Hu G,Pukac L,Liu D,Ni J,Kim S,Gentz R,Feng P,Moore PA,Ruben SM,Wei P.TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator,Immunity,2002,16(3):479-492.
7 Yang CR,Hsieh SL,Teng CM,Ho FM,Su WL,Lin WW.Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A,a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.Cancer Res,2004,64(3):1122-1129.
8 Simonet WS,Lacey DL,Dunstan CR,Kelley M,Chang MS,Luthy R,Nguyen HQ,Wooden S,Bennett L,Boone T,Shimamoto G, DeRoseM,Elliott R,Colombero A,Tan HL,Trail G,Sullivan J,Davy E,Bucay N,Renshaw-Gegg L,Hughes TM,Hill D,Pattison W,Campbell P,Sander S,VanG,Tarpley J,DerbyP,Lee R,Boyle WJ.Osteoprotegerin:a novel secreted protein involved in the regulation of bone density.Cell,1997,89(2):309-319.
9 Onyia JE,Galvin RJ,Ma YL,Halladay DL,Miles RR,Yang X,Fuson T,Cain RL,Zeng QQ,Chandrasekhar S,Emkey R,Xu Y,Thirunavukkarasu K,Bryant HU,Martin TJ.Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption.J Pharmacol Exp Ther,2004,309(1):369-379.
10 Degli-Esposti MA,Smolak PJ,Walczak H,Waugh J,Huang CP,DuBose RF,Goodwin RG,Smith CA.Cloning and characterization of TRAIL-R3,a novel member of the emerging TRAIL receptor family.J Exp Med,1997,186(7):1165-1170.
11 Ruiz de Almodovar C,Lopez-Rivas A,Redondo JM,Rodriguez A.Transcriptional regulation of the TRAIL-R3 gene.Vitam Horm,2004,67(1):51-63.
12 Smith CA,Davis T,Anderson D,Solam L,Beckmann MP,Jerzy R,Dower SK,Cosman D,Goodwin RG.A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.Science,1990,248(4958):1019-1023.
13 Idriss HT,Naismith JH.TNF alpha and the TNF receptor superfamily:structure-function relationship(s).Microsc Res Tech,2000,50(3):184-195.
14 Howard ST,Chan YS,Smith GL.Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family.Virology,1991,180(2):633-647.
15 Hu FQ,Smith CA,Pickup DJ.Cowpox virus contains two copies of an early gene encoding a soluble secreted form of the type Ⅱ TNF receptor.Virology,1994,204(1):343-356.
16 Brunetti CR,Paulose-Murphy M,Singh R,Qin J,Barrett JW,Tardivel A,Schneider P,Essani K,McFadden G.A secreted high-affinity inhibitor of human TNF from Tanapox virus.Proc Natl Acad Sci U S A,2003,100(8):4831-4836.
17 Gruss HJ,Dower SK.Tumor necrosis factor ligand superfamily:involvement in the pathology of malignant lymphomas.Blood,1995,85(12):3378-3404.
18 Goetz FW,Planas JV,MacKenzie S.Tumor necrosis factors.Dev Comp Immunol,2004,28(5):487-497.
19 Pitti RM,Marsters SA,Lawrence DA,Roy M,Kischkel FC,Dowd P,Huang A,Donahue CJ,Sherwood SW,Baldwin DT,Godowski PJ,Wood WI,Gurney AL,Hillan KJ,Cohen RL,Goddard AD,Botstein D,Ashkenazi A.Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.Nature,1998,396(6712):699-703.
20 Bai C,Connolly B,Metzker ML,Hilliard CA,Liu X,Sandig V,Soderman A,Galloway SM,Liu Q,Austin CP,Caskey CT.Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.Proc Natl Acad Sci U S A,2000,97(3):1230-1235.
21 Schwendel A,Richard F,Langreck H,Kaufmann O,Lage H,Winzer KJ,Petersen I,Dietel M.Chromosome alterations in breast carcinomas:frequent involvement of DNA losses including chromosomes 4q and 21q.Br J Cancer,1998,78(6):806-811.
22 Richard F,Pacyna-Gengelbach M,Schluns K,Fleige B,Winzer KJ,Szymas J,Dietel M,Petersen I,Schwendel A.Patterns of chromosomal imbalances in invasive breast cancer.Int J Cancer,2000,89(3):305-310.
23 Sakakura C,Mori T,Sakabe T,Ariyama Y,Shinomiya T,Date K, Hagiwara A, Yamaguchi T, Takahashi T, Nakamura Y, Abe T, Inazawa J. Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer, 1999, 24(4):299-305.
24 Altura RA, Maris JM, Li H, Boyett JM, Brodeur GM, Look AT. Novel regions of chromosomal loss in familial neuroblastoma by comparative genomic hybridization. Genes Chromosomes Cancer, 1997, 19(3): 176-184.
25 Shinomiya T, Mori T, Ariyama Y, Sakabe T, Fukuda Y, Murakami Y, Nakamura Y, Inazawa J. Comparative genomic hybridization of squamous cell carcinoma of the esophagus: the possible involvement of the DPI gene in the 13q34 amplicon. Genes Chromosomes Cancer, 1999 , 24(4):337-344.
26 Fujita Y, Sakakura C, Shimomura K, Nakanishi M, Yasuoka R, Aragane H, Hagiwara A, Abe T, Inazawa J, Yamagishi H. Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology, 2003, 50(54): 1857-1863.
27 Wroblewski VJ, McCloud C, Davis K, Manetta J, Micanovic R, Witcher DR. Pharmacokinetics , metabolic stability , and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)] , in cynomolgus monkeys and mice. Drug Metab Dispos, 2003, 31(4):502-507.
28 Wroblewski VJ, Witcher DR, Becker GW, Davis KA, Dou S, Micanovic R, Newton CM, Noblitt TW, Richardson JM, Song HY, Hale JE. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT. Biochem Pharmacol, 2003, 65(4):657-667.
29 Otsuki T, Tomokuni A, Sakaguchi H, Aikoh T, Matsuki T, Isozaki Y,Hyodoh F,Ueki H,KusakaM,Kita S,Ueki A.Over-expression of the decoy receptor 3(DcR3)gene in peripheral blood mononuclear cells(PBMC)derived from silicosis patients.Clin Exp Immunol,2000,119(2):323-327.
30 Kim S,McAuliffe WJ,Zaritskaya LS,Moore PA,Zhang L,Nardelli B.Selective induction of tumor necrosis factor 6/decoy receptor 3 release by bacterial antigens in human monocytes and myeloid dendritic cells.Infection and Immunity,2004,72(1):89-93.
31 Li H,Zhang L,Lou H,Ding I,Kim S,Wang L,Huang J,Di Sant'Agnese PA,Lei JY.Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus.Am J Clin Pathol,2005,124(2):282-287.
32 Kim S,Fotiadu A,Kotoula V.Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.Clin Immunol,2005,115(3):286-294.
33 Maeda T,Hao C,Tron VA.Ultraviolet light(UV)regulation of the TNF family decoy receptors DcR2 and DcR3 in human keratinocytes.J Cutan Med Surg,2001,5(4):294-298.
34 Wu Y,Han B,Sheng H,Lin M,Moore PA,Zhang J,Wu J.Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.Int J Cancer,2003,105(5):724-732.
35 陈罡,罗殿中.原发性肝细胞癌中诱捕受体3的过度表达及临床意义.广东医学,2006,27(10):1438-1440.
36 Takahama Y,Yamada Y,Emoto K,Fujimoto H,Takayama T,Ueno M,Uchida H,Hirao S,Mizuno T,Nakajima Y.The prognostic significance of overexpression of the decoy receptor for Fas ligand(DcR3)in patients with gastric carcinomas.Gastric Cancer,2002,5(2):61-68.
37 Elnemr A,Ohta T,Yachie A,Kayahara M,Kitagawa H,Fujimura T,Ninomiya I,Fushida S,Nishimura GI,Shimizu K,Miwa K.Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway.Int J Oncol,2001,18(2):311-316.
38 Ibrahim SM,Ringel J,Schmidt C,Ringel B,Muller P,Koczan D,Thiesen HJ,Lohr M.Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.Pancreas,2001,23(1):72-79.
39 Tsuji S,Hosotani R,Yonehara S,Masui T,Tulachan SS,Nakajima S,Kobayashi H,Koizumi M,Toyoda E,Ito D,Kami K,Mori T,Fujimoto K,Doi R,Imamura M.Endogenous decoy receptor 3blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.Int J Cancer,2003,106(1):17-25.
40 Roth W,Isenmann S,Nakamura M,Platten M,Wick W,Kleihues P,Bahr M,Ohgaki H,Ashkenazi A,Weller M.Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95ligand-induced apoptosis and chemotaxis.Cancer Res,2001,61(6):2759-2765.
41 Arakawa Y,Tachibana O,Hasegawa M,Miyamori T,Yamashita J,Hayashi Y.Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.Acta Neuropathol(Berl),2005,109(3):294-298.
42 Ohshima K,Haraoka S,Sugihara M,Suzumiya J,Kawasaki C,Kanda M,Kikuchi M.Amplification and expression of a decoy receptor for fas ligand(DcR3)in virus(EBV or HTLV-Ⅰ)associated lymphomas.Cancer Lett,2000,160(1):89-97.
43 Shen HW,Gao SL,Wu YL,Peng SY.Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.World J Gastroenterol,2005,11(38):5926-5930.
44吴育连,于俊秀,沈宏伟,韩冰,高顺良.血清TR6升高与胃癌淋巴转移分期的关系.中华外科杂志,2003,41(12):928-931.
45 Mild G,Bachmann F,Boulay JL,Glatz K,Laffer U,Lowy A,Metzger U,Reuter J,Terracciano L,Herrmann R,Rochlitz C.DcR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer,lnternational Journal of Cancer,2002,102(3):254-257.
46陈罡,罗殿中,王云,廖芝玲,张美艳.肝细胞癌中DcR3表达和癌细胞凋亡的关系研究.中华病理学杂志,2007,36(2):113-117.
47 Shi G,Wu Y,Zhang J,Wu J.Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo.J Immunol,2003,171(7):3407-3414.
48 Wan X,Shi G,Semenuk M,Zhang J,Wu J.DcR3/TR6 modulates immune cell interactions.Journal of cellular biochemistry,2003,89(3):603-612.
49 Chang YC,Hsu TL,Lin HH,Chio CC,Chiu AW,Chen NJ,Lin CH,Hsieh SL.Modulation of macrophage differentiation and activation by decoy receptor 3.Journal of leukocyte biology,2004,75(3):486-494.
50 Yang CR,Wang JH,Hsieh SL,Wang SM,Hsu TL,Lin WW.Decoy receptor 3(DcR3)induces osteoclast formation from monocyte/macrophage lineage precursor cells.Cell Death Differ,2004,11(Suppl 1):S97-107.
51 Yang CR,Hsieh SL,Teng CM,Ho FM,Su WL,Lin WW.Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A,a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action.Cancer Res,2004,64(3):1122-1129.
52吴泰璜,段伟宏,苏忠学,吴亚光.反义DcR3 RNA转染诱导肝癌细胞凋亡的作用.中华微生物学和免疫学杂志,2005,25(10):799-802.
53段伟宏,苏忠学,吴泰璜.DcR3反义RNA与顺铂对肝癌细胞凋亡影响的比较。中国现代普通外科进展,2005,8(2):90-92.
54 Takahashi T,Tanaka M,Inazawa J,Abe T,Suda T,Nagata S.Human Fas ligand:gene structure,chromosomal location and species specificity,Int Immunol,1994,6(10):1567-1574.
55 Ju ST,Panka DJ,Cui H,Ettinger R,el-Khatib M,Sherr DH,Stanger BZ,Marshak-Rothstein A.Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.Nature,1995,373(6513):444-448.
56 Gajate C,Fonteriz RI,Cabaner C,Alvarez-Noves G,Alvarez-Rodriguez Y,Modolell M,Mollinedo F.Intracellular triggering of Fas,independently of FasL,as a new mechanism of antitumor ether lipid-induced apoptosis,lnt J Cancer,2000,85(5):674-682.
57 Gajate C,Del Canto-Janez E,Acuna AU,Amat-Guerri F,Geijo E,Santos-Beneit AM,Veldman RJ,Mollinedo F.Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis.J Exp Med,2004,200(3):353-365.
58 Gajate C,Mollinedo F.The antitumor ether lipid ET-18-OCH(3)induces apoptosis through translocation and capping of Fas/CD95into membrane rafts in human leukemic cells.Blood,2001,98(13):3860-3863.
59 Kusakabe K,Otsuki Y,Kiso Y.Involvement of the fas ligand and fas system in apoptosis induction of mouse uterine natural killer cells.J Reprod Dev,2005,51(3):333-340.
60 Smyth MJ,Cretney E,Kelly JM,Westwood JA,Street SE,Yagita H,Takeda K,van Dommelen SL,Degli-Esposti MA,Hayakawa Y.Activation of NK cell cytotoxicity.Mol Immunol,2005,42(4):501-510.
61 Pinkoski MJ,Brunner T,Green DR,Lin T.Fas and Fas ligand in gut and liver.Am J Physiol Gastrointest Liver Physiol,2000,278(3):354-366.
62 Suda T,Okazaki T,Naito Y,Yokota T,Arai N,Ozaki S,Nakao K,Nagata S.Expression of the Fas ligand in cells of T cell lineage.J Immunol,1995,154(8):3806-3813.
63 Siegel RM,Chan FK,Chun HJ,Lenardo MJ.The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity.Nat Immunol,2000,1(6):469-474.
64 Zaks TZ,Chappell DB,Rosenberg SA,Restifo NP.Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor:selective rescue by caspase inhibition.J Immunol,1999,162(6):3273-3279.
65 Karas M,Zaks TZ,Yakar S,Dudley ME,LeRoith D.TCR stimulation protects CD_8~+T cells from CD95 mediated apoptosis.Hum Immunol,2001,62(1):32-38.
66 Wahlsten JL,Gitchell HL,Chan CC,Wiggert B,Caspi RR.Fas and Fas ligand expressed on cells of the immune system,not on the target tissue,control induction of experimental autoimmune uveitis.J Immunol,2000,165(10):5480-5486.
67 Beyaert R,Van Loo G,Heyninck K,Vandenabeele P.Signaling to gene activation and cell death by tumor necrosis factor receptors and Fas.Int Rev Cytol,2002,214(1):225-272.
68 Sheikh MS,Fornace AJ Jr.Death and decoy receptors and p53-mediated apoptosis.Leukemia,2000,14(8):1509-1513.
69 Zhang J,Salcedo TW,Wan X,Ullrich S,Hu B,Gregorio T,Feng P,Qi S,Chen H,Cho YH,Li Y,Moore PA,Wu J.Modulation of T-cell responses to alloantigens by TR6/DcR3.J Clin Invest,2001,107(11):1459-1468.
70 Hayashi S,Miura Y,Nishiyama T,Mitani M,Tateishi K,Sakai Y,Hashiramoto A,Kurosaka M,Shiozawa S,Doita M.Decoy receptor 3 expressedin rheumatoid synovial fibroblasts protects the cells against fas-induced apoptosis.Arthritis Rheum,2007,56(4):1067-1075.
71 ConnollyK,Cho YH,Duan R,Fikes J,Gregorio T,LaFleur DW,Okoye Z,Salcedo TW,Santiago G,Ullrich S,Wei P,Windle K,Wong E,Yao XT,Zhang YQ,Zheng G,Moore PA.In vivo inhibition of Fas ligand-mediated killing by TR6,a Fas ligand decoy receptor.J Pharmacol Exp Ther,2001,298(1):25-33.
72 Wortinger MA,Foley JW,Larocque P,Witcher DR,Lahn M,Jakubowski JA,Glasebrook A,SongHY.Fas ligand-induced murine pulmonary inflammation is reduced by a stable decoy receptor 3analogue.Immunology,2003,110(2):225-233.
73 Mauri DN,Ebner R,Montgomery RI,Kochel KD,Cheung TC,Yu GL,Ruben S,Murphy M,Eisenberg RJ,Cohen GH,Spear PG,Ware CF.LIGHT,a new member of the TNF superfamily,and lymphotoxin alpha are ligands for herpesvirus entry mediator.Immunity,1998,8(1):21-30.
74 Gill RM,Ni J,Hunt JS.Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes.Am J Pathol,2002,161(6):2011-2017.
75 Wan X,Zhang J,Luo H,Shi G,Kapnik E,Kim S,Kanakaraj P,Wu J.A TNF family member LIGHT transduces costimulatory signals into human T cells.J Immunol,2002,169(12):6813-6821.
76 Ware CF.Network communications:lymphotoxins,LIGHT,and TNF.Annu Rev Immunol.2005,23:787-819.
77 Morel Y,Truneh A,Costello RT,Olive D.LIGHT,a new TNF superfamily member,is essential for memory T helper cell-mediated activation of dendritic cells.Eur J Immunol,2003,33(11):3213-3219.
78 Yang D,Zhai Y,Zhang M.LIGHT,a new member of the TNF superfamily.J Biol Regul Homeost Agents,2002,16(3):206-210.
79 Chang YH,Hsieh SL,Chao Y,Chou YC,Lin WW.Proinflammatory effects of LIGHT through HVEM and LTbetaR interactions in cultured human umbilical vein endothelial cells.J Biomed Sci,2005,12(2):363-3?5.
80 Bamias G,Martin C 3rd,Marini M,Hoang S,Mishina M,Ross WG,Sachedina MA,Friel CM,Mize J,Bickston SJ,Pizarro TT,Wei P,Cominelli F.Expression,localization,and functional activity of TLIA,a novel Th1-polarizing cytokine in inflammatory bowel disease.J Immunol,2003,171(9):4868-4874.
81 Wen L,Zhuang L,Luo X,Wei P.TLiA-inducedNF-kappaB activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1cells.J Biol Chem,2003,278(40):39251-39258.
82 Green DR.Apoptosis.Death deceiver.Nature,1998,396(6712):629-630.
83 Wu YY,Chang YC,Hsu TL,Hsieh SL,Lai MZ.Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3.The Journal of Biological Chemistry,2004,279(42):44211 -44218.
84 Shi G,Luo H,Wan X,Salcedo TW,Zhang J,Wu J.Mouse T cells receive costimulatory signals from LIGHT,a TNF family member.Blood,2002,100(9):3279-3286.
85 Hsu MJ,Lin WW,Tsao WC,Chang YC,Hsu TL,Chiu AW,Chio CC,Hsieh SL.Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3.Experimental Cell Research,2004,292(2):241-251.
86 Hsu TL,Chang YC,Chen SJ,Liu YJ,Chiu AW,Chio CC,Chen L,Hsieh SL.Modulation of dendritic cell differentiation and maturation by decoy receptor 3.Journal of Immunology,2002,168(10):4846-4853.
87 Yang CR,Hsieh SL,Ho FM,Lin WW.Decoy receptor increases monocyte adhesion to endothelial cells via NF-κB-dependent up-regulation of intercellular adhesion molecule-1,VCAM-1,and IL-8expression.Journal of Immunology,2005,174(3):1647-1656.
88 Hwang SL,Lin CL,Cheng CY,LinFA,Lieu AS,Howng SL,Lee KS.Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery.Kaohsiung J Med Sci,2004,20(3):124-127.
89 Shi G,Mao J,Yu G,Zhang J,Wu J.Tumor vaccine based on cell surface expression of DcR3/TR6.Journal of Immunology,2005,174(8):4727-4735.
90 Wu SF,Liu TM,Lin YC,Sytwu HK,Juan HP,Chen ST,Shen KL,Hsi SC,Hsieh SL.Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice:from regulatory mechanism to clinical implication.Journal of Biology,2004,75(2):293-306.
91 Wu Y,Han B,Luo H,Roduit R,Salcedo TW,Moore PA,Zhang J,Wu J.DcR3/TR6 effectively prevent islet primary nonfunction after transplantation.Diabetes,2003,52(9):2279-2286.
92 Sung HH,Juang JH,Lin YC,Kuo CH,Hung JT,Chen A,Chang DM,Chang SY,Hsieh SL,Sytwu HK.Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice.The Journal of Experimental Medicine,2004,199(8):1143-1151.